{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from os.path import dirname, realpath\n",
    "import sys\n",
    "import subprocess\n",
    "import re\n",
    "import datetime\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "from nltk.corpus import stopwords\n",
    "from pycorenlp import StanfordCoreNLP\n",
    "from  nltk.parse  import CoreNLPParser\n",
    "\n",
    "sys.path.insert(0, dirname(realpath('')))\n",
    "from helper_functions import synparse, tregex_tsurgeon"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Replace with standardized filenames when pipeline for previous task is ready\n",
    "filenames = ['DrugVisData.csv']\n",
    "\n",
    "data_dir = '../data/'\n",
    "out_dir = '../data/output/'\n",
    "# tregex_dir = '../stanford-tregex-2018-02-27/'\n",
    "\n",
    "# negated term list (use the human annotated version)\n",
    "neg_list = pd.read_csv(data_dir + 'neg_list_complete.txt', sep='\\t', header=0)\n",
    "neg = neg_list['ITEM'].values\n",
    "neg_term = [' ' + item + ' ' for item in neg]\n",
    "neg_term.extend(item + ' ' for item in neg)\n",
    "\n",
    "stopwords = stopwords.words('english')\n",
    "RM_POS = ['NN', 'NNS', 'RB', 'NP', 'ADVP', 'IN']\n",
    "RM_CP = ['however', 'although', 'but']\n",
    "\n",
    "nlp = StanfordCoreNLP('http://localhost:9001')\n",
    "parser = CoreNLPParser(url='http://localhost:9001')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# tree rules\n",
    "\n",
    "trts = {}\n",
    "# no \"jvd|murmurs|deficits\" not work, pleural -> vbz?\n",
    "# trts['NP'] = ('NP=target << DT=neg <<, /no|without/ !> NP >> TOP=t >> S=s', \\\n",
    "#               'excise s target,delete neg')\n",
    "\n",
    "# if np with top node=S???\n",
    "# trts['NP'] = ('NP=target << DT=neg <<, /no|without/ !> NP >> TOP=t >> S=s', \\\n",
    "#               'excise s target,delete neg')\n",
    "trts['NP'] = ('NP=target << DT=neg <<, /no|without/ !> NP >> TOP=t', \\\n",
    "              'delete neg')\n",
    "# if np with top node=NP\n",
    "trts['NP-nS'] = ('NP=target <<, /DT|NN|RB/=neg <<, /no|without/ !> NP >> TOP=t', \\\n",
    "              'delete neg')\n",
    "\n",
    "\n",
    "# denies -> mis pos to nns\n",
    "trts['NP-denies'] = ('NP=target <<, /denies|deny|denied/=neg >> TOP=t', \\\n",
    "              'delete neg')\n",
    "\n",
    "# vp only\n",
    "trts['VP-A'] = ('VP=target << /VBZ|VBD|VB/=neg >> TOP=t', \\\n",
    "              'delete neg')\n",
    "trts['VP-CC'] = ('VP=target <<, /VBZ|VBD|VB/=neg < CC >> TOP=t', \\\n",
    "              'delete neg')\n",
    "# vp only, 'resolved', add that neg1 part to prevent jvd -> VP, rashes -> VP error pos tagging\n",
    "# trts['VP-P'] = ('NP=target <<, DT=neg1 <<, /no|negative|not/ $ VP=neg2 >> TOP=t >> S=s', \\\n",
    "#               'delete neg1')\n",
    "trts['VP-P'] = ('VP=vp <<- /free|negative|absent|ruled|out|doubtful|unlikely|excluded|resolved|given/=neg $ NP=head >> TOP=t >> S=s', \\\n",
    "              'excise s head')\n",
    "# this is post, ... is negative\n",
    "# trts['ADJP-P'] = ('VP=vp < ADJP <<- /negative/=neg $ NP=target >> TOP=t >> S=s', \\\n",
    "#                 'delete vp,excise s target')\n",
    "trts['ADJP-P'] = ('VP=vp <<- /free|negative|absent|ruled|out|doubtful|unlikely|excluded|resolved|given/=neg $ NP=head >> TOP=t >> S=s', \\\n",
    "                'excise s head')\n",
    "# this is ant, negative for ...\n",
    "# trts['ADJP-A'] = ('PP=head $ JJ=neg < NP=target >> TOP=t > ADJP=s', \\\n",
    "#                 'delete neg')\n",
    "trts['ADJP-A'] = ('PP=head $ /JJ|ADJP|NP/=neg <- NP=target >> TOP=t >> /S|NP|ADJP/=s', \\\n",
    "                'excise s target')\n",
    "# not\n",
    "# trts['ADVP-P'] = ('VP=target <<, /VB*|MD/ $ RB=neg >> TOP=t >> S=s', \\\n",
    "#                 'excise s target')\n",
    "trts['ADVP-P'] = ('VP=head $ RB=neg <<, /VB*|MD/=be >> TOP=t >> S=s', \\\n",
    "                'delete head,delete neg')\n",
    "\n",
    "# trts['ADVP-A'] = ('VP=target <<, /VB*|MD/ $ RB=neg >> TOP=t >> S=s', \\\n",
    "#                 'excise s target')\n",
    "trts['ADVP-A'] = ('VP=head $ RB=neg <<, /VB*|MD/ >> TOP=t >> S=s', \\\n",
    "                'excise s head')\n",
    "trts['ADVP-A2'] = ('VP=head << RB=neg <<, /VB*|MD/ << /ADJP|VP/=target >> TOP=t >> S=s', \\\n",
    "                'excise s target')\n",
    "# remove sbar\n",
    "trts['ADVP-sbar'] = ('PP=head <<, /of|without/=neg > NP $ NP < NP=target >> TOP=t >> NP=st << SBAR=sbar', \\\n",
    "                'excise st target,delete sbar')\n",
    "trts['ADVP-advp'] = ('ADVP=advp', \\\n",
    "                'delete advp')\n",
    "trts['forced-sbar'] = ('SBAR=sbar', \\\n",
    "                'delete sbar')\n",
    "\n",
    "# remove RB\n",
    "trts['ADVP-RB'] = ('TOP=target <<, RB=neg', \\\n",
    "                'delete neg')\n",
    "\n",
    "# sob become this, so need to be after np and vp\n",
    "# trts['PP'] = ('PP=head <<, /of|without/=neg > NP $ NP < NP=target >> TOP=t >> NP=s', \\\n",
    "#               'excise s target')\n",
    "trts['PP'] = ('PP=head <<, IN=neg1 < NP=target >> TOP=t >> /S|NP|ADJP/=s $ /JJ|NP/=neg2', \\\n",
    "              'excise s target')\n",
    "trts['PP-2'] = ('PP=head << IN=neg <<, /of|without/ >> TOP=t', \\\n",
    "                'delete neg')\n",
    "\n",
    "trts['NP-CC'] = ('S=s < NP =head<< PP=target << DT=neg <<, /no|without/ < CC=but << but < S=rm < /\\.|\\,/=punct << SBAR=sbar !> NP > TOP=t', \n",
    "                 'delete neg,delete sbar,delete punct,delete but,delete rm')\n",
    "trts['NP-although'] = ('S=s < NP =head<< PP=target << DT=neg <<, /no|without/ << /although|but/ < /\\.|\\,/=punct << SBAR=sbar !> NP > TOP=t', \n",
    "                       'delete neg,delete sbar,delete punct')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2020-04-07 15:09:54.776459\n",
      ">> b'not recommended , because of the wide range of severe side effects associated with their use\\r\\n'\n",
      ">> b'not always recorded ; 6/29 dogs ( 21 % ) did not receive regular treatment , 7/29 were treated regularly with isoxazoline systemic products ( 24 % ) , 2/29 with fipronil-based spot-ons ( 7 % ) and 2/29 ( 7 % ) with collars ( one flumethrin-based and one unrecorded brand ) .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no evidence supporting its use , which could actually be associated with concerning gastrointestinal dysbiosis\\r\\n'\n",
      ">> b'not treated with terbinafine .\\r\\n'\n",
      ">> b'Patients were excluded\\r\\n'\n",
      ">> b'no licensed vaccines or alternative therapeutic options are available to prevent disease or treat patients\\r\\n'\n",
      ">> b'no licensed vaccines or alternative therapeutic options are available to prevent disease or treat patients\\r\\n'\n",
      ">> b'no licensed vaccines or alternative therapeutic options are available to prevent disease or treat patients\\r\\n'\n",
      ">> b'Total RNA was treated with RNAse-free\\r\\n'\n",
      ">> b'without post-exposure prophylaxis did so after the administration of an aggressive combination of medical treatments including the induction of a therapeutic coma , combined with ribavirin , ketamine , and amantadine treatment\\r\\n'\n",
      ">> b'without post-exposure prophylaxis did so after the administration of an aggressive combination of medical treatments including the induction of a therapeutic coma , combined with ribavirin , ketamine , and amantadine treatment\\r\\n'\n",
      ">> b'not exist\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not exist ,\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'no convincing evidence that these agents reduce mortality in patients receiving thrombolytic therapy and aspirin ( Tables I , II , A and II , B )\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'no convincing evidence that these agents reduce mortality in patients receiving thrombolytic therapy and aspirin ( Tables I , II , A and II , B )\\r\\n'\n",
      ">> b'without affecting the voiding reflex\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'nonvoiding bladder contractions during the storage phase , whereas capsaicin had no inhibitory effects on reflex bladder contractions in spinal intact cats\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not respond to erythromycin therapy that was used because of a penicillin allergy -LSB- 16 -RSB-\\r\\n'\n",
      ">> b'not shown here , such as theophylline tests , verapamil tests , etc. .\\r\\n'\n",
      ">> b'not shown here , such as theophylline tests , verapamil tests , etc. .\\r\\n'\n",
      ">> b\"not shown here such as (`` `` NYH Lab Procedure : Iron ('' '' and (`` `` NYH Lab Procedure : Magnesium . ('' ''\\r\\n\"\n",
      "--- remove CP\n",
      ">> b'no therapeutic effect ,\n",
      "--- forced remove SBAR\n",
      ">> b'no therapeutic effect , the administration of dexamethasone ( 3 \\xe2\\x88\\x92 5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days ) temporarily improved the fecal characteristics for a period of several days\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no therapeutic effect , the administration of dexamethasone ( 3 \\xe2\\x88\\x92 5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days ) temporarily improved the fecal characteristics for a period of several days\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no therapeutic effect , the administration of dexamethasone ( 3 \\xe2\\x88\\x92 5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days ) temporarily improved the fecal characteristics for a period of several days\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no therapeutic effect , the administration of dexamethasone ( 3 \\xe2\\x88\\x92 5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days ) temporarily improved the fecal characteristics for a period of several days\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no therapeutic effect , the administration of dexamethasone ( 3 \\xe2\\x88\\x92 5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days ) temporarily improved the fecal characteristics for a period of several days\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no therapeutic effect , the administration of dexamethasone ( 3 \\xe2\\x88\\x92 5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days ) temporarily improved the fecal characteristics for a period of several days\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no therapeutic effect , the administration of dexamethasone ( 3 \\xe2\\x88\\x92 5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days ) temporarily improved the fecal characteristics for a period of several days\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no therapeutic effect , the administration of dexamethasone ( 3 \\xe2\\x88\\x92 5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days ) temporarily improved the fecal characteristics for a period of several days\\r\\n'\n",
      ">> b'not more elevated in patients treated with ribavirin and IFN-\\xce\\xb1\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'now be added the idea of the use of nicotine in a sociably acceptable manner , and preliminary studies in our laboratory in tumor-bearing rats show promising results ( Personal observations , Laviano and Meguid , 2005 )\\r\\n'\n",
      ">> b'not in the median eminence in middle-aged and aged ones ( 312 ) , indicating a shifting interaction between the opiate system and sex hormones with age .\\r\\n'\n",
      ">> b'not in the median eminence in middle-aged and aged ones ( 312 ) , indicating a shifting interaction between the opiate system and sex hormones with age .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not that of apomorphine , so that the K receptors did not interact with dopamine in this situation ( 370 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not that of apomorphine , so that the K receptors did not interact with dopamine in this situation ( 370 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not that of apomorphine , so that the K receptors did not interact with dopamine in this situation ( 370 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not affected by DAMGO , DPDPE , or U50 ,488 , suggesting none & the three major opiate receptor types mediated it ( (NP-TMP 488 ) ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not affected by DAMGO , DPDPE , or U50 ,488 , suggesting none & the three major opiate receptor types mediated it ( (NP-TMP 488 ) ,\n",
      "--- forced remove SBAR\n",
      ">> b'nonopiate mechanism , because naloxone had no effect on it ( 449 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not affected by chronic treatment with amphetamine ( 27 ) , indicating that there was no interaction between the opiate system and amphetamine in this situation .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not change with age in children ( 374 ) , even when it is given IT ( 30 , 374 ) , a route previously reporting to have no effect\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not intraventricularly ( ICV ) , suggesting that the opiate effect was probably at the spinal cord level ( 339 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not upregulation of the endogenous opiate system , because whole milk had a stronger effect than skim milk , despite the fact that equal volumes of it were consumed ( 554 )\\r\\n'\n",
      ">> b'not in others ( 179 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not alter the suppression of running by shock , indicating that it is probably an opiate effect ( 550 )\\r\\n'\n",
      ">> b'not affect measures of ~ - endorphin ( 133 ) , short-term administration of haloperidol in therapy did increase them\\r\\n'\n",
      ">> b'not affect measures of ~ - endorphin ( 133 ) , short-term administration of haloperidol in therapy did increase them\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'with no adverse effects ( 169 ) , so that GHB may be useful at least in the short term .\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'with no adverse effects ( 169 ) , so that GHB may be useful at least in the short term .\\r\\n'\n",
      ">> b'not by naloxonazine , naltrindole , or nor-binaltorphimine , indicating ~ 2 mediation of the response ( 75 )\\r\\n'\n",
      ">> b'no change in the ability of IT morphine to suppress ventilatory responses to CO2 between the ages of 4 months and 15 years ( (NP-TMP 374 ) .\\r\\n'\n",
      "--- remove CP\n",
      ">> b'not only their offspring\n",
      "--- forced remove SBAR\n",
      ">> b'not received the pairing , indicating that morphine can act as a conditioned stimulus ( 59 )\\r\\n'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ">> b'not just the opiate system ( 347 )\\r\\n'\n",
      "--- remove CP\n",
      ">> b'not only for achieving optimal benefi t\n",
      "--- remove CP\n",
      ">> b'not only for achieving optimal benefi t\n",
      ">> b\"noff et al ) 914 Cold boxes-making of , 300 Colitis , ulcerative -- cyclosporin in ( Gupta et al ) ( C ) 1277 ; seasonality of ( Myszor and Calam ) ( C ) 522 , ( Don and Goldacre ) ( C ) 1156 ; water-ski spill and ( Bundgaard and Jarnum ) ( C ) 1157 College of Health-alternative medicine guide , 1484 Colon cancer-and breast cancer ( Levine and Witte ) ( C ) 222 , ( Wilhams ) ( C ) ( Frohne and Pfander ) ( Hannmgton-Kiff ) ( R ) 556 Government statement , 1228 ; overheating and ( Stanton ) 1199 , ( Cohen ) ( C ) 1403 ; in SE Scotland ( Bain and Bartholomew ) ( C ) 1402 ; ventilatory dysfunction and ( E ) 558 Cotinine-urine levels in babies , maternal passive smoking and ( Woodward et al ) ( C ) 935 Co-trimoxazole-toxicity of ( Jick et al ) ( C ) 631 , ( Lennon ) ( C ) 1152 , Shann ) ( C ) 1477 Cotsides-use of ( E ) 383 C-reactive protein -- predictor m meningitis ( Borchsemus et al ) ( C ) 864 ; in bacterial with viral meningitis ( Zegher et al ) ( C ) 1465 Crohn 's disease -- seasonality of ( Myszor and Calam ) ( C ) 522 , ( Don and Goldacre ) ( C ) 1156 Cryptorehidism -- circulating pituitary autoantibodies in ( Poupland-Barthelaix et al ) ( C ) 631 Cryptosporidosis -- in AIDS , amprolium for ( Veldhuyzen van Zanten et al ) ( C ) 346 ; in calves and handlers ( Rahaman et al ) ( C ) ( Anderson ) ( C ) 159 ; metyrapone and sodium valproate for ( Glaser et al ) ( C ) 640 ; sodium valproate for ( Cavagnini et al ) ( C ) 162 Cyclamates-carcinogenicity of , 881 Cyclophosphamide-in adjuvant breast cancer therapy ( Howell et al ) 307 Cyclosporin-blood levels and complications ( Irschik et al ) ( C ) 692 ; interaction with rifampicin ( Daniels et al ) ( C ) 639 ; interstitial fibrosis with in renal graft ( Klintmalm et al ) 950 , ( Farnsworth et al ) ( C ) 1470 , after liver graft , haemolytic uraemic syndrome with ( Bonser et al ) ( C ) 1337 ; measurement of ( Holt and White ) ( C ) 228 , ( Albano et al ) ( C ) 408 , ( Woloszczuk et al ) ( C ) ( Harper et al ) ( C ) 981 ; for red-cell aplasia ( Totterman et al ) ( C ) 693 ; in renal transplantation ( Salaman ) 269 , ( Ballardie et al ) ( C ) 639 ; in renal transplantation in children ( Klare et al ) ( C ) 692 , in ulcerative colitis ( Gupta et al ) ( C ) 1277 Cystic fibrosis-fetal cholecystokinin and ( Gosden and Gosden ) 541 , ( Brock ) ( C ) 815 , ( Gosden and Gosden ) ( C ) 815 , ( Cantor et al ) ( C ) 1039 , ( Gosden and Gosden ) ( C ) 1273 ; meconium ileus and ( Muller et al ) ( C ) 223 , ( Barson et a -RSB- ) ( C ) 472 ; screening for ( Mastala et al ) ( C ) 575 ; survival in ( Anderson ) ( C ) 292 , ( Wilcken ) ( C ) 292 , ( Littlewood and Miller ) ( C ) 816 Cytarabine -- and HLA-DR antigen expression in leukaemia ( Pinto et al ) ( C ) 867 ; low-dose , for leukaemia in the elderly ( Harousseau et al ) ( C ) ( Pedersen and M & oslash ; lsted-Pedersen ) ( C ) 1284 ; sucrose in mixed meals ( Slama et at ) 122 , ( Ferner ) ( C ) 585 , ( Heaton et at ) ( C ) 585 , ( Slama ) ( C ) ( C ) 1389 Diazoxide-serum androgens with ( Hallengren and H&ouml;kfelt ) ( C ) 1044 Diet-and CHD , DHSS report ( E ) 143 ; and CHD mortality rates in USA ( Le Fanu ) ( C ) 634 ; and hypertension ( E ) 671 , ( Rosenberg and Coleman ) ( C ) 1334 ; and market forces , GLC report , 416 ; and myocardial metabolism ( Thuesen et al ) 59 , ( Frick ) ( C ) 515 ; protein restricted in renal failure ( Rosman et at ) ) 1 1291 ; salt in , and hypertension ( Brown et at ) ( C ) 456 , ( Bush ) ( C ) 634 , ( Finn ) ( C ) 634 , ( Hughes-Davies ) ( C ) 634 , ( Michell ) ( C ) 634 , ( Smith ) ( C ) 634 , ( E ) 671 , ( de Wardener ) ( C ) 688 , ( MacGregor ) ( C ) ( Watt and Hart ) ( C ) 877 , ( Beard et al ) ( C ) ( Swaminathan ) 1329 ; antibiotic resistance ( Lacey ) 1022 ; drugs , diagnostic aids and vaccines ( Murray ) 1194 , human genetics ( White ) 1257 ; human molecular biology ( Weatherall ) 1440 ; human perfectibility ( Rose ) 1380 ; and immune system ( Rabbitts ) 1086 ; message of ( Wolpert ) 853 ; oncogenes ( Weiss and Marshall ) 1138 ; probes in diagnosis ( Steel ) ( Barnes ) ( C ) 1102 , ( Mathews ) ( C ) 1102 , ( Smith ) ( C ) 1102 , ( Roddie ) ( C ) 1476 , ( Schwartz ) ( C ) ( C ) 528 , ( Sargeaunt ) ( C ) 818 Enteral and Tube Feeding ( Rombeau and Caldwell ) ( Goode ) ( R ) 261 Environmental health-asphalt production and lung cancer ( Wilson ( C ) 354 ; detergents and the gut ( E ) 384 , ( Clark ) ( C ) 525 , ( Roe ) ( Morgan et al ) ( C ) 232 , ( Stephenson ) ( C ) damage to at Bhopal disaster ( Andersson et al ( C ) 1481 , damage to from Christmas trees ( Brazier ) ( C ) ( Rowland et al ) ( C ) 1150 ; and medical research ( Chye and Ratnam ) ( C ) 231 ; ovulation induction in ( Porter et al ) ( C ) 1284 , pregnancy from , oestrogens and prognosis in ( Emperaire et al ) ( C ) 1151 ; see also Warnock Report Fertility -- after sex change ( Dewhurst and Gordon ) ( C ) 1461 & agr ; - fetoprotein -- maternal serum levels ( Johnson and Lingley ) ( C ) ( Mayne ) ( C ) 1221 .\\r\\n\"\n",
      ">> b'without 17-hydroxyprogesterone ) and low-dose dexamethasone suppression\\r\\n'\n",
      ">> b'not cure the disease\\r\\n'\n",
      ">> b'not cure the disease\\r\\n'\n",
      ">> b'not emerge during treatment\\r\\n'\n",
      ">> b'without affecting the high level of IL-1 ( Kurokawa , et al. , 1996a ; Kurokawa , et al. , 1996b ; Kurokawa , et al. , 1998 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not occur in the G-string , and this J o u r n (NP-TMP a l P r e - p r o o f difference in the mode of chain termination and proofreading activity causes a lower mutation frequency in subjects treated with penciclovir and ganciclovir than in subjects treated with acyclovir .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not occur in the G-string , and this J o u r n (NP-TMP a l P r e - p r o o f difference in the mode of chain termination and proofreading activity causes a lower mutation frequency in subjects treated with penciclovir and ganciclovir than in subjects treated with acyclovir .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not occur in the G-string , and this J o u r n (NP-TMP a l P r e - p r o o f difference in the mode of chain termination and proofreading activity causes a lower mutation frequency in subjects treated with penciclovir and ganciclovir than in subjects treated with acyclovir .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not occur in the G-string , and this J o u r n (NP-TMP a l P r e - p r o o f difference in the mode of chain termination and proofreading activity causes a lower mutation frequency in subjects treated with penciclovir and ganciclovir than in subjects treated with acyclovir .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not occur in the G-string , and this J o u r n (NP-TMP a l P r e - p r o o f difference in the mode of chain termination and proofreading activity causes a lower mutation frequency in subjects treated with penciclovir and ganciclovir than in subjects treated with acyclovir .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not occur in the G-string , and this J o u r n (NP-TMP a l P r e - p r o o f difference in the mode of chain termination and proofreading activity causes a lower mutation frequency in subjects treated with penciclovir and ganciclovir than in subjects treated with acyclovir .\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'no drugs available to treat these coronaviruses , with current evidence suggesting that the antiviral drugs ribavirin and interferon ( IFN ) are only slightly efficacious in ameliorating SARS-CoV or MERS-CoV infections ( (NP-TMP 2 )\\r\\n'\n",
      ">> b'no antidepressant properties for any patients ( Alexopoulos 2001 )\\r\\n'\n",
      ">> b'For virus passaging , the collected supernatant was treated with 10 \\xc2\\xb5g/ml trypsin ( Type IX , Sigma , #T0303 ) for 30 min at 37 \\xc2\\xb0C , diluted (NP-TMP 5 times with serum-free\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not been conducted , tylosin administered in drinking water has been shown to reach concentrations in serum and lung well above MIC concentrations\\r\\n'\n",
      ">> b'not eliminate the carrier state .\\r\\n'\n",
      ">> b'not been proven\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'Any calf diagnosed and previously treated with antibiotics or flunixin meglumine for BRD or any other disease was excluded\\r\\n'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- forced remove SBAR\n",
      ">> b'Any calf diagnosed and previously treated with antibiotics or flunixin meglumine for BRD or any other disease was excluded\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not induce oocysts shedding in cats recently or chronically experimentally infected with T gondii\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not induce oocysts shedding in cats recently or chronically experimentally infected with T gondii\\r\\n'\n",
      "--- remove CP\n",
      ">> b'not only for the tumors to be visualized by PET ,\n",
      "--- remove CP\n",
      ">> b'not only for the tumors to be visualized by PET ,\n",
      ">> b'not be used to treat CMV infections\\r\\n'\n",
      ">> b'not meet the criteria for immunoprophylaxis\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'Hepatitis has been reported from use of unprocessed refrigerated and frozen bone allografts ,\n",
      ">> b'no source was identified ?\\r\\n'\n",
      ">> b'not rec ~ mrnended .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'~ ~ Children who are found to be infected with Mycobacterium tuberculosis should be excluded\\r\\n'\n",
      ">> b'no source was identified ?\\r\\n'\n",
      ">> b'not rec ~ mrnended .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'~ ~ Children who are found to be infected with Mycobacterium tuberculosis should be excluded\\r\\n'\n",
      ">> b'not administered\\r\\n'\n",
      ">> b'not administered\\r\\n'\n",
      ">> b'not administered\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not planning to be vaccinated against influenza , receiving immunosuppressive medications ( including cancer chemotherapy , oral corticosteroid use (NP-TMP .21 days , methotrexate , post-transplant medications and/or anti-cytokine or B-lymphocyte depletion therapies ) , or expected to die within 30 days , as determined by the supervising physician\\r\\n'\n",
      ">> b'Brie \\xc2\\xaf y , total RNA was extracted by guanidine thiocyanate ( Promega ) and dissolved in RNAse-free\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'absence of patients who received other types of treatment\\r\\n'\n",
      ">> b'not produce neutralizing antibodies -LSB- 14 -RSB-\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'nother open-label study examined a combination of hydroxychloroquine and methotrexate in the treatment of CHIKV arthritis and found that some patients partially responded to therapy ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'nother open-label study examined a combination of hydroxychloroquine and methotrexate in the treatment of CHIKV arthritis and found that some patients partially responded to therapy ,\n",
      ">> b'not reside on humans for any extended periods\\r\\n'\n",
      ">> b'not reside on humans for any extended periods\\r\\n'\n",
      ">> b'not the specific allergen ) and the forced expiratory volume in one second ( FEV1 ) are commonly used to evaluate the degree of airway impairment and the response to bronchodilators , glucocorticoids , and other therapeutic agents\\r\\n'\n",
      ">> b'no proven effective antiviral therapies for LCM infection , intravenous ribavirin therapy reduces mortality in patients infected with Lassa fever virus ( a member of the Old World Arenavirus serocomplex ) and may be of some benefit in patients with severe LCMV infections ( Andrei and De Clercq 1993 ; McCormick et al\\r\\n'\n",
      ">> b'no proven effective antiviral therapies for LCM infection , intravenous ribavirin therapy reduces mortality in patients infected with Lassa fever virus ( a member of the Old World Arenavirus serocomplex ) and may be of some benefit in patients with severe LCMV infections ( Andrei and De Clercq 1993 ; McCormick et al\\r\\n'\n",
      ">> b'without the use of an adjuvant\\r\\n'\n",
      ">> b'no abnormality and the cat was treated with dexamethasone and mannitol\\r\\n'\n",
      ">> b'no abnormality and the cat was treated with dexamethasone and mannitol\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'no single agent has consistently been effective in all cases , existing data suggest that cidofovir and its lipid ester analogs ( CMX001 or brincidofovir ) are most effective in managing adenovirus infections\\r\\n'\n",
      ">> b'115 Thus alteration of antimicrobial dosing does not appear\\r\\n'\n",
      ">> b'no acid methyl ester isocyanate ( 20 mmol )\\r\\n'\n",
      ">> b'no acid methyl ester isocyanate ( 20 mmol )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b\"no effect or to decrease the incidence of NEC in treated patients compared with infants receiving placebo .25 j 60 * 82j I ('' '' Nonetheless , multiple antibioticresistant stool organisms have emerged from the treated patients\\r\\n\"\n",
      "--- forced remove SBAR\n",
      ">> b\"no effect or to decrease the incidence of NEC in treated patients compared with infants receiving placebo .25 j 60 * 82j I ('' '' Nonetheless , multiple antibioticresistant stool organisms have emerged from the treated patients\\r\\n\"\n",
      "--- forced remove SBAR\n",
      ">> b'not able to confirm that NEC was due to theophylline therapy in newborn infants (NP-TMP .4 s Interestingly , the theophylline-treated group consisted of younger and more immature patients ; thus , as a group they would be expected to have a higher incidence of NEC\\r\\n'\n",
      ">> b'no better than patients treated with ampicillin and gentamicin alone\\r\\n'\n",
      ">> b'no better than patients treated with ampicillin and gentamicin alone\\r\\n'\n",
      ">> b'no better than patients treated with ampicillin and gentamicin alone\\r\\n'\n",
      ">> b'without IFN-b and then assessed for control of encephalomyocarditis virus ( EMCV ) levels and virus-induced cytopathic effect\\r\\n'\n",
      ">> b'not treated and unchallenged , untreated control groups and two experimental ones ( E1 and E2 ) both treated with diammonium glycyrrhizic acid , extracted from licorice with added vitamins and oligoelements , and as in-feed medication\\r\\n'\n",
      ">> b'not treated and unchallenged , untreated control groups and two experimental ones ( E1 and E2 ) both treated with diammonium glycyrrhizic acid , extracted from licorice with added vitamins and oligoelements , and as in-feed medication\\r\\n'\n",
      ">> b'not administer heparin for thromboprophylaxis .\\r\\n'\n",
      ">> b'not impair responsiveness to steroids\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'The REG cells were transiently transfected with Hsp27 deletion mutant plasmids for 48h and treated after this with docetaxel ( 1nM ) and the same protocol was used for transfection of Hsp27 phosphorylation mutant plasmids , treated with docetaxel ( 10 nM ) in serum-free\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'The REG cells were transiently transfected with Hsp27 deletion mutant plasmids for 48h and treated after this with docetaxel ( 1nM ) and the same protocol was used for transfection of Hsp27 phosphorylation mutant plasmids , treated with docetaxel ( 10 nM ) in serum-free\\r\\n'\n",
      ">> b'cleared of infection with praziquantel , 150 mg/kg PO administered once daily for three consecutive days -LSB- 31 -RSB- .\\r\\n'\n",
      ">> b'not clinical signs of disease are present (NP-TMP -LSB- 2 , 20 -RSB- .\\r\\n'\n",
      ">> b'absence of a therapeutic target\\r\\n'\n",
      ">> b'not prohibited\\r\\n'\n",
      ">> b'not prohibited\\r\\n'\n",
      ">> b'not clearly superior to interferon alone .\\r\\n'\n",
      ">> b'not responding to either oseltamivir or zanamivir antiviral therapy .\\r\\n'\n",
      "--- remove CP\n",
      ">> b'not cured\n",
      "--- remove CP\n",
      ">> b'not cured\n",
      ">> b'not have a strong effect on 2019-nCoV\\r\\n'\n",
      ">> b'not feasible or not desirable\\r\\n'\n",
      ">> b'not manage at home , often indicated by the failure to improve with frequent albuterol use over a 2-or 3-day period\\r\\n'\n",
      ">> b'not , itraconazole is highly lipid soluble , and may penetrate the CNS and become tissue bound\\r\\n'\n",
      ">> b'not be the optimal treatment for pneumonia\\r\\n'\n",
      ">> b'not be the optimal treatment for pneumonia caused by toxin-producing CA-MRSA\\r\\n'\n",
      ">> b'not transcription\\r\\n'\n",
      ">> b'not transcription\\r\\n'\n",
      ">> b'no longer a good option for empirical therapy in RTI of pneumococcal aetiology\\r\\n'\n",
      ">> b'not achieved -LSB- 452 -RSB-\\r\\n'\n",
      ">> b'not achieved -LSB- 452 -RSB-\\r\\n'\n",
      ">> b'not achieved -LSB- 452 -RSB-\\r\\n'\n",
      ">> b'not achieved -LSB- 452 -RSB-\\r\\n'\n",
      ">> b'not likely to share a similar pathogenesis of liver injury\\r\\n'\n",
      ">> b'not likely to share a similar pathogenesis of liver injury\\r\\n'\n",
      ">> b'not been recommended as a therapeutic decision factor ( Jensen et al. , 2006 ; Pawlotsky , 2012 )\\r\\n'\n",
      ">> b'not been recommended as a therapeutic decision factor ( Jensen et al. , 2006 ; Pawlotsky , 2012 )\\r\\n'\n",
      ">> b'not been recommended as a therapeutic decision factor ( Jensen et al. , 2006 ; Pawlotsky , 2012 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'The long term estrogen deprived human breast cancer cell line MCF-7:5 C (NP-TMP -LSB- 9 , 12 -RSB- was cloned from parental MCF-7 cells following long term ( > (NP-TMP 12 months ) culture in estrogen-free\\r\\n'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- forced remove SBAR\n",
      ">> b'The long term estrogen deprived human breast cancer cell line MCF-7:5 C (NP-TMP -LSB- 9 , 12 -RSB- was cloned from parental MCF-7 cells following long term ( > (NP-TMP 12 months ) culture in estrogen-free\\r\\n'\n",
      ">> b'not use antiviral drugs to treat flu patients prior to the 2009/A/H1N1 pandemic and were generally unfamiliar with these drugs ( Tamiflu and Relenza )\\r\\n'\n",
      ">> b'not been shown to decrease the mortality rate in Turkey\\r\\n'\n",
      ">> b'not treated with ribavirin died ( 58.3 % ) ; this difference was statistically significant\\r\\n'\n",
      ">> b'not been done\\r\\n'\n",
      ">> b'not been done\\r\\n'\n",
      ">> b'not been done\\r\\n'\n",
      ">> b'absence of the anti-hCD26 antibody\\r\\n'\n",
      ">> b'not the equivalent S region of BatCoV ( C ) An antibody blocking assay using HKU4 pseudoviruses treated with 10 mg/ml trypsin and an anti-hCD26 antibody\\r\\n'\n",
      ">> b'without a cytotoxic alkylating agent such as chlorambucil or cyclophosphamide ( Table 10 -3 ) .\\r\\n'\n",
      ">> b'without a cytotoxic alkylating agent such as chlorambucil or cyclophosphamide ( Table 10 -3 ) .\\r\\n'\n",
      ">> b'no effect on URTIs caused by other respiratory viruses .\\r\\n'\n",
      ">> b'no effect on URTIs caused by other respiratory viruses .\\r\\n'\n",
      ">> b'not improve\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no approved LF vaccine and therapeutic options are limited to intravenous or oral ribavirin , which is often impractical in endemic areas\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not possible from existing data to conclusively demonstrate that oseltamivir in addition to appropriate antibiotic therapy improves outcomes in patients with documented bacterial co-infection ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not possible from existing data to conclusively demonstrate that oseltamivir in addition to appropriate antibiotic therapy improves outcomes in patients with documented bacterial co-infection ,\n",
      ">> b'not inhibit hepatic metabolism of other drugs .\\r\\n'\n",
      ">> b'not inhibit hepatic metabolism of other drugs .\\r\\n'\n",
      ">> b'not inhibit hepatic metabolism of other drugs .\\r\\n'\n",
      ">> b'not normalize in the face of a maximum or high CVP ( > 10 cm H 2 O ) , dobutamine should be administered as a \\xce\\xb2-agonist inotrope ( 2 to 20 \\xce\\xbcg/kg / minute )\\r\\n'\n",
      ">> b'no longer followed in the United Kingdom -LSB- 53 -RSB- .\\r\\n'\n",
      ">> b'not edible and the addictiveness of nicotine also makes it unsuitable for oral delivery of therapeutic proteins\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no active ingredient in Bangladesh , which was discovered only due to abnormally high numbers of treatment failures ( 304 , 308 )\\r\\n'\n",
      ">> b'not hydrolyzed in the small intestine ) , and noted a lower cecal pH and a reduced incidence of enteritis\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not require antibiotic treatment , contrary to systemic infection which could be treated using trimethoprim-sulfamethoxazole ( no resistant strain reported ) or fluoroquinolones , despite the fact that a few resistant strains have been reported\\r\\n'\n",
      ">> b'not to be contagious to others\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not approved for this use and might be overused by some who hope the drug will cure all infections of dairy cattle\\r\\n'\n",
      ">> b'no scientific confirmation of their value in treating DIC , and in fact they may have deleterious effects in patients with DIC .\\r\\n'\n",
      ">> b'no scientific confirmation of their value in treating DIC , and in fact they may have deleterious effects in patients with DIC .\\r\\n'\n",
      ">> b'not responded to previous quinidine therapy : Digoxin 0.86 \\xce\\xbcg/kg per hour or 11.0 \\xce\\xbcg/kg thrice daily IV for 4 to 5 days\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'PLA-PEG Zidovudine Solvent evaporation Less phagocytosis -LSB- 21 -RSB- PLA-TPGS Paclitaxel Modified solvent extraction/evaporation Initial burst followed by sustained release -LSB- 24 -RSB- PLA-mPEG Salting out Less interaction with leukocytes -LSB- 123 -RSB- PLA-PEG-PLA Savoxepine Salting out Controlled drug release up to 1 week -LSB- 124 -RSB- PLA BSA Salting out/coacervation High encapsulation efficiency and acceptable burst release -LSB- 125 -RSB- PLA Cloricromene Nanoprecipitation Faster dissolution than free\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'PLA-PEG Zidovudine Solvent evaporation Less phagocytosis -LSB- 21 -RSB- PLA-TPGS Paclitaxel Modified solvent extraction/evaporation Initial burst followed by sustained release -LSB- 24 -RSB- PLA-mPEG Salting out Less interaction with leukocytes -LSB- 123 -RSB- PLA-PEG-PLA Savoxepine Salting out Controlled drug release up to 1 week -LSB- 124 -RSB- PLA BSA Salting out/coacervation High encapsulation efficiency and acceptable burst release -LSB- 125 -RSB- PLA Cloricromene Nanoprecipitation Faster dissolution than free\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'PLA-PEG Zidovudine Solvent evaporation Less phagocytosis -LSB- 21 -RSB- PLA-TPGS Paclitaxel Modified solvent extraction/evaporation Initial burst followed by sustained release -LSB- 24 -RSB- PLA-mPEG Salting out Less interaction with leukocytes -LSB- 123 -RSB- PLA-PEG-PLA Savoxepine Salting out Controlled drug release up to 1 week -LSB- 124 -RSB- PLA BSA Salting out/coacervation High encapsulation efficiency and acceptable burst release -LSB- 125 -RSB- PLA Cloricromene Nanoprecipitation Faster dissolution than free\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'PLA-PEG Zidovudine Solvent evaporation Less phagocytosis -LSB- 21 -RSB- PLA-TPGS Paclitaxel Modified solvent extraction/evaporation Initial burst followed by sustained release -LSB- 24 -RSB- PLA-mPEG Salting out Less interaction with leukocytes -LSB- 123 -RSB- PLA-PEG-PLA Savoxepine Salting out Controlled drug release up to 1 week -LSB- 124 -RSB- PLA BSA Salting out/coacervation High encapsulation efficiency and acceptable burst release -LSB- 125 -RSB- PLA Cloricromene Nanoprecipitation Faster dissolution than free\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'PLA-PEG Zidovudine Solvent evaporation Less phagocytosis -LSB- 21 -RSB- PLA-TPGS Paclitaxel Modified solvent extraction/evaporation Initial burst followed by sustained release -LSB- 24 -RSB- PLA-mPEG Salting out Less interaction with leukocytes -LSB- 123 -RSB- PLA-PEG-PLA Savoxepine Salting out Controlled drug release up to 1 week -LSB- 124 -RSB- PLA BSA Salting out/coacervation High encapsulation efficiency and acceptable burst release -LSB- 125 -RSB- PLA Cloricromene Nanoprecipitation Faster dissolution than free\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'PLA-PEG Zidovudine Solvent evaporation Less phagocytosis -LSB- 21 -RSB- PLA-TPGS Paclitaxel Modified solvent extraction/evaporation Initial burst followed by sustained release -LSB- 24 -RSB- PLA-mPEG Salting out Less interaction with leukocytes -LSB- 123 -RSB- PLA-PEG-PLA Savoxepine Salting out Controlled drug release up to 1 week -LSB- 124 -RSB- PLA BSA Salting out/coacervation High encapsulation efficiency and acceptable burst release -LSB- 125 -RSB- PLA Cloricromene Nanoprecipitation Faster dissolution than free\\r\\n'\n",
      ">> b'no pancreatic nodules were evident during surgery .\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not only because of poor feed intake ,\n",
      ">> b'without issue\\r\\n'\n",
      ">> b'nogenicity of influenza vaccine in 34 children with chronic arthritis and in 13 healthy controls and no differences in antibody titers after vaccination were observed between children with chronic arthritis and controls , nor among patients treated with DMARDS and/or prednisone -LSB- 6 -RSB- .\\r\\n'\n",
      ">> b'without justification , 2 were administered ceftriaxone , 1 received azithromycin , and another received amoxicillin\\r\\n'\n",
      ">> b'without justification , 2 were administered ceftriaxone , 1 received azithromycin , and another received amoxicillin\\r\\n'\n",
      ">> b'without justification , 2 were administered ceftriaxone , 1 received azithromycin , and another received amoxicillin\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not undergo ovariectomy \\xe2\\x80\\xa2 Melatonin induces apoptosis of rat prolactin-secreting tumors\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not undergo ovariectomy \\xe2\\x80\\xa2 Melatonin induces apoptosis of rat prolactin-secreting tumors\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not undergo ovariectomy \\xe2\\x80\\xa2 Melatonin induces apoptosis of rat prolactin-secreting tumors\\r\\n'\n",
      ">> b'no licensed RSV vaccine is available ( (NP-TMP 7 ) , and the only approved specific therapy , palivizumab ( anti-RSV antibody ) , has limited uses among infants at high risk for severe respiratory illness in high-resource settings ( 8 ) .\\r\\n'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ">> b'without EDTA and were resuspended to final concentration of 1 \\xc3\\x97 10 5 cells/ml\\r\\n'\n",
      ">> b'not recovered the righting reflex within 60 minutes after surgery , or became apnoeic postoperatively , were administered naloxone or atipamezole , depending on the group assignment\\r\\n'\n",
      ">> b'not recovered the righting reflex within 60 minutes after surgery , or became apnoeic postoperatively , were administered naloxone or atipamezole , depending on the group assignment\\r\\n'\n",
      ">> b'not have an impact on pain scoring (NP-TMP 3 hours after surgery .\\r\\n'\n",
      ">> b'not have an impact on pain scoring (NP-TMP 3 hours after surgery .\\r\\n'\n",
      ">> b'with no apparent effect on fecal viral shedding\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'no FDA-licensed vaccines against arenaviruses and the only available antiviral therapy is limited to the use of ribavirin that is partially effective\\r\\n'\n",
      ">> b'not been used since July 2005 to minimize drug toxicity during HDCT .\\r\\n'\n",
      ">> b'Infants with inherited metabolic diseases may require alternative forms of nutrition : neonates with classic galactosemia owing to deficiency of galactose-1-phosphate uridyltransferase should receive lactose-free\\r\\n'\n",
      "--- remove CP\n",
      ">> b'not only as a spice and tea ,\n",
      "--- forced remove SBAR\n",
      ">> b'not benefited from or are intolerant of standard CMV therapies , or whose virus is resistant to ganciclovir and foscarnet\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not benefited from or are intolerant of standard CMV therapies , or whose virus is resistant to ganciclovir and foscarnet\\r\\n'\n",
      ">> b'not abbreviated by the development of resistance\\r\\n'\n",
      ">> b'The protein bands were subject to in-gel trypsin digestion after being treated with iodoacetamide to alkylate free\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not available for broad distribution in countries where LASV is endemic ( Mccormick et al. , 1986 ) .\\r\\n'\n",
      ">> b'not receiving methylphenidate ( Ritalin ) , six children were taking prescribed doses of methylphenidate , and the remaining six children had their medications reduced by half after 2 weeks\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not be distinguished by otoscopic examination , AOM is usually treated empirically , using antibiotics such as amoxicillin that have a high concentration in the middle ear fluid\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not receive steroid therapy , and 10 patients ( 23 % ) received ribavirin/interferon\\r\\n'\n",
      ">> b'notherapy ( n = (NP-TMP 26 ) , dual ther apy with ribavirin ( n = (NP-TMP 24 ) and triple therapy with additional amantadine 200 mg/day ( n = (NP-TMP 25 ) , amantadine did not increase the frequency or severity of adverse effects ( 132 C ) .\\r\\n'\n",
      ">> b'notherapy ( n = (NP-TMP 26 ) , dual ther apy with ribavirin ( n = (NP-TMP 24 ) and triple therapy with additional amantadine 200 mg/day ( n = (NP-TMP 25 ) , amantadine did not increase the frequency or severity of adverse effects ( 132 C ) .\\r\\n'\n",
      "--- remove CP\n",
      ">> b'without amantadine 200 mg/day , viral load fell more markedly in the group taking triple therapy including amantadine ,\n",
      "--- remove CP\n",
      ">> b'without amantadine 200 mg/day , viral load fell more markedly in the group taking triple therapy including amantadine ,\n",
      "--- forced remove SBAR\n",
      ">> b'no worse than placebo ( 127 M Comparative studies In a randomized controlled trial in patients with chronic hepatitis C treated with interferon-alfa 2a alone ( n = (NP-TMP 53 ) , with amantadine 100 mg bd ( n = (NP-TMP 111 ) , with ribavirin ( n = (NP-TMP 106 ) or with amantadine \\xc3\\xbe ribavirin ( n = (NP-TMP 108 ) , there was a sustained virological response in 13 % , 6 % , 18 % , and 22 % respectively ( 130 C )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no worse than placebo ( 127 M Comparative studies In a randomized controlled trial in patients with chronic hepatitis C treated with interferon-alfa 2a alone ( n = (NP-TMP 53 ) , with amantadine 100 mg bd ( n = (NP-TMP 111 ) , with ribavirin ( n = (NP-TMP 106 ) or with amantadine \\xc3\\xbe ribavirin ( n = (NP-TMP 108 ) , there was a sustained virological response in 13 % , 6 % , 18 % , and 22 % respectively ( 130 C )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no worse than placebo ( 127 M Comparative studies In a randomized controlled trial in patients with chronic hepatitis C treated with interferon-alfa 2a alone ( n = (NP-TMP 53 ) , with amantadine 100 mg bd ( n = (NP-TMP 111 ) , with ribavirin ( n = (NP-TMP 106 ) or with amantadine \\xc3\\xbe ribavirin ( n = (NP-TMP 108 ) , there was a sustained virological response in 13 % , 6 % , 18 % , and 22 % respectively ( 130 C )\\r\\n'\n",
      ">> b'not zanamivir ) administered orally , intraperitoneally ( Ono 2008 ; Ono 2013 ) and intracerebroventricularly ( Ono 2013 )\\r\\n'\n",
      ">> b'not zanamivir ) administered orally , intraperitoneally ( Ono 2008 ; Ono 2013 ) and intracerebroventricularly ( Ono 2013 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not discount the potential benefit of using zanamivir and oseltamivir in individuals under particular situations , for example in immunocompromised or in compassionate cases , where few other therapeutic options may exist\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not discount the potential benefit of using zanamivir and oseltamivir in individuals under particular situations , for example in immunocompromised or in compassionate cases , where few other therapeutic options may exist\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not discount the potential benefit of using zanamivir and oseltamivir in individuals under particular situations , for example in immunocompromised or in compassionate cases , where few other therapeutic options may exist\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not discount the potential benefit of using zanamivir and oseltamivir in individuals under particular situations , for example in immunocompromised or in compassionate cases , where few other therapeutic options may exist\\r\\n'\n",
      ">> b'non-toxic concentrations of pentoxifylline were determined by administering intraperitoneally (NP-TMP 50 , 100 , 200 and 300 mg/kg body weight of the compound to different groups ( n = (NP-TMP 4 per group ) of 4-week-old Swiss albino mice\\r\\n'\n",
      ">> b'with no vaccines and only one FDA approved drug , nitazoxanide , available\\r\\n'\n",
      ">> b'without even mentioning the demand of efficient strategies of disease control under agricultural conditions\\r\\n'\n",
      ">> b'not yet registered for use in cattle\\r\\n'\n",
      ">> b'absence of the NA activity , virus spreading from an infected cell to adjacent cells was dramatically suppressed by omission of trypsin , essential for maturation of HA , from the experimental condition ( Figure 4A )\\r\\n'\n",
      ">> b'without HA activation by trypsin treatment ( Figure 4A )\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not lower IOP in normal cats when administered (NP-TMP every 12 hours\n",
      ">> b'not receive oseltamivir therapy , having favourable outcome\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no significant change in circulating IGF-1 levels when the DPP-IV inhibitor sitagliptin was administered to pigs for three days ( 44 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not satisfactory and the clinical limitation of current antiviral drugs for HBV , such as lamivudine , has caused rapid emergence of drug-resistant viral strains during the prolonged therapeutic treatment\\r\\n'\n",
      ">> b'without adverse consequences , by adding rifampin to standard antistaphylococcal antimicrobial therapy\\r\\n'\n",
      ">> b'not show BCV shedding or diarrhea\\r\\n'\n",
      ">> b'neither clinical signs of BCV infection , BCV shedding , nor seroconversion ( Table 1 )\\r\\n'\n",
      ">> b'not in the ICU or ceftazidime plus erythromycin when in the ICU\\r\\n'\n",
      ">> b'not in the ICU or ceftazidime plus erythromycin when in the ICU\\r\\n'\n",
      ">> b'not in the ICU or ceftazidime plus erythromycin when in the ICU\\r\\n'\n",
      ">> b'not in the ICU or ceftazidime plus erythromycin when in the ICU\\r\\n'\n",
      ">> b'not considered to be a drug for empiric therapy of CAP , since it is being used as an agent against MRSA arising in both the hospital and the community .\\r\\n'\n",
      ">> b'At 4 days post-administration , peritoneal macrophages from treated and control mice were harvested by peritoneal lavage as described before and were incubated for an additional 3 days in phenol red-free\\r\\n'\n",
      ">> b'not show benefit\\r\\n'\n",
      ">> b'not show benefit\\r\\n'\n",
      ">> b'not show benefit\\r\\n'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ">> b'no proven effective therapy for unclassified interstitial pneumonia with fibrosis , recommended treatments include supportive care and immunosuppressive therapies such as corticosteroids , cyclophosphamide , and vincristine\\r\\n'\n",
      ">> b'no proven effective therapy for unclassified interstitial pneumonia with fibrosis , recommended treatments include supportive care and immunosuppressive therapies such as corticosteroids , cyclophosphamide , and vincristine\\r\\n'\n",
      ">> b'no proven effective therapy for unclassified interstitial pneumonia with fibrosis , recommended treatments include supportive care and immunosuppressive therapies such as corticosteroids , cyclophosphamide , and vincristine\\r\\n'\n",
      ">> b'no proven effective therapy for unclassified interstitial pneumonia with fibrosis , recommended treatments include supportive care and immunosuppressive therapies such as corticosteroids , cyclophosphamide , and vincristine\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not significantly reduce the incidence of seizures , it did seem to reduce the severity of seizures in a study\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'no reports demonstrating that acyclovir is effective in CVB myocarditis .\\r\\n'\n",
      ">> b'no effectiveness\\r\\n'\n",
      ">> b'noea , myalgia , malaise , rhinorrhoea , arthralgia , chest pain , headache , and vomiting ) , vital signs at ICU admission ( heart rate , respiratory rate , blood pressure ) , laboratory values on admis sion ( haemoglobin concentration , lymphocyte count , platelet count , arterial blood gas analysis , FiO 2 , partial pressure of oxygen ( PaO 2 ) , and lactate concen tration ) , coexisted infection , treatment ( oxygen therapy , vaso constrictive agents , antiviral agents , antibacterial agents , cortico steroids , and immuno globulin ) , as well as living status\\r\\n'\n",
      ">> b'not with 10 mg/mL of L - ( tosylamido-2-phenyl ) ethyl chloromethyl ketone ( TPCK ) - treated trypsin ( Sigma ) at 37uC for 15 minutes to activate S protein\\r\\n'\n",
      ">> b'no acid-based therapeutics approved by the US Food and Drug Administration ( FDA ) , are shown in Figure 2A\\r\\n'\n",
      ">> b'no acid-based therapeutics approved by the US Food and Drug Administration ( FDA ) , are shown in Figure 2A\\r\\n'\n",
      ">> b'no acid-based therapeutics Figure 2A ) and Leuprolide ( PDB ID : 1YY2 ; Figure 2B ) were obtained from the Protein Data Bank ( PDB ; http://www\\r\\n'\n",
      ">> b'no et al. , 2018 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'noted that 3 of 4 patients with A ustus who survived received voriconazole combined with caspofungin ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'noted that 3 of 4 patients with A ustus who survived received voriconazole combined with caspofungin ,\n",
      ">> b'no therapy was shown to reduce mortality\\r\\n'\n",
      ">> b'nol-induced myocardial infarction using male albino Wistar rats -LSB- 167 -RSB- , the therapeutic benefit of inhibiting the release of bGLU , other lysosomal enzymes and pro-inflammatory cytokines was evident in the restoration of near-normal myocardial histology and function , compared to diseased controls\\r\\n'\n",
      ">> b'not optimal\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'absence of identified bacterial infection was reported as a rare complication in early clinical trials of single-agent bleomycin , 14 and at least 4 cases with a similar constellation of symptoms leading to fatal cardiorespiratory collapse in patients with lymphoma treated with bleomycin containing regimens were reported in the 1970s and 1980s\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not only were specific IgE production and release of histamine from mast cells suppressed ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not only were specific IgE production and release of histamine from mast cells suppressed ,\n",
      ">> b'Macrophages were washed once with serum-free\\r\\n'\n",
      "--- remove CP\n",
      ">> b'not only doxorubicin\n",
      "--- remove CP\n",
      ">> b'not only doxorubicin\n",
      ">> b'SCID mice bearing size-matched , CL1-5-derived xenografts were treated with ( 1 ) SP5-2-conjugated liposomal doxorubicin ( SP5-2-LD ) , ( 2 ) mutant peptide-conjugated liposomal doxorubicin ( MP5-2-LD ) , ( 3 ) non-targeted liposomal doxorubicin ( LD ) , ( 4 ) free\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not grow any microorganisms and the patient did not show clinical improvement following antimicrobial therapy\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not grow any microorganisms and the patient did not show clinical improvement following antimicrobial therapy\\r\\n'\n",
      ">> b'not have any effect on HANLCD63 release\\r\\n'\n",
      ">> b'not show greater protection than monotherapy against seasonal influenza ( mainly H3N2 ) infection in humans ( Duval et al. , 2010 )\\r\\n'\n",
      ">> b'not present\\r\\n'\n",
      ">> b'not present\\r\\n'\n",
      ">> b'not to exceed 5 mg/kg\\r\\n'\n",
      ">> b'not remain under 6.4 , administer urine acidifiers such as ammonium chloride , 800 mg / day or Y < teaspoonful on food , or methionine , 500 mg q12h\\r\\n'\n",
      ">> b'without treatment\\r\\n'\n",
      ">> b'nol residue ( CMR ) vaccine , and vaccinia/Hantaan vaccine have been administered to no more than a few hundred volunteers each .\\r\\n'\n",
      ">> b'no respiratory symptoms appeared after 3 months , even after cessation of treatments\\r\\n'\n",
      ">> b'We excluded\\r\\n'\n",
      ">> b'We excluded\\r\\n'\n",
      ">> b'no clinical benefit of amantadine-based combination therapy was found in comparison to standard of care ( peg-IFN\\xce\\xb1 plus ribavirin ) -LSB- 97 -RSB-\\r\\n'\n",
      ">> b'no clinical benefit of amantadine-based combination therapy was found in comparison to standard of care ( peg-IFN\\xce\\xb1 plus ribavirin ) -LSB- 97 -RSB-\\r\\n'\n",
      ">> b'not responding to the triple therapy -LSB- 71 -RSB-\\r\\n'\n",
      ">> b'without 250 kU/ml of Lysozyme ( Lyz ) in TGF buffer -LSB- 100 mM Tris-HCl pH. 8 , 50 mM glucose , 1 % FBS ( v/v ) ( Hyclone , South Logan , UT ) -RSB- for 30 min\\r\\n'\n",
      ">> b'not receive therapy\\r\\n'\n",
      ">> b'no significant clinical improvements have been reported in humans treated with amiodarone during the Western African EBOV epidemic ( (NP-TMP 2013-2016 ) (NP-TMP -LSB- 66 , 67 -RSB-\\r\\n'\n",
      ">> b'not during an acute exacerbation and skin prick testing using standardized allergens -LSB- 12 -RSB-\\r\\n'\n",
      ">> b'free of symptoms afterward .\\r\\n'\n",
      ">> b'free of symptoms afterward .\\r\\n'\n",
      ">> b'no clinical experience for this indication -LSB- (NP-TMP 60 , 73 , 85 -RSB- 4\\r\\n'\n",
      ">> b'no clinical experience for this indication -LSB- (NP-TMP 60 , 73 , 85 -RSB- 4\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'without a priori information , while the NGS deep sequencing technique provided in-depth knowledge into the upper respiratory microbiota and host gene expression in response to virus infection\\r\\n'\n",
      ">> b'not cholesterol , reversed this resistance\\r\\n'\n",
      ">> b'not cholesterol , reversed this resistance\\r\\n'\n",
      ">> b'not been implicated .\\r\\n'\n",
      ">> b'not improve\\r\\n'\n",
      ">> b'not improve\\r\\n'\n",
      "--- remove CP\n",
      ">> b'not significantly different considering drug classes ;\n",
      "--- forced remove SBAR\n",
      ">> b'noted that the results in Figures 1 and S1 do not account for central stockpiles which might be mobilized in the event of a pandemic , as discussed later ) .\\r\\n'\n",
      ">> b'without 16 nM bortezomib overnight ( 18 h ) at 37 \\xc2\\xb0C and were used as target cells ; 1 \\xc3\\x97 10 6 E7-specific CTLs were incubated with the target cells at a 10:1 ( E : T ) ratio for 4.5 h\\r\\n'\n",
      ">> b'no randomized control trials comparing the benefits of adding IVIG to ribavirin therapy\\r\\n'\n",
      ">> b'notherapy for RSV infections in adult HCT recipients\\r\\n'\n",
      ">> b'test for BRAF mutations in low-grade gliomas ( for diagnosis ) , colorectal cancer ( to establish the sporadic origin of MSI-H tumors and response to anti-EGFR therapy ) , hairy cell leukemia ( for diagnosis ) , lung adenocarcinomas ( to predict response to therapy ) , thyroid cancer ( for preoperative detection of thyroid cancer in FNA samples and prognosis in papillary thyroid carcinoma ) , or melanoma ( to predict response to BRAF kinase inhibitors ) .\\r\\n'\n",
      ">> b'test for BRAF mutations in low-grade gliomas ( for diagnosis ) , colorectal cancer ( to establish the sporadic origin of MSI-H tumors and response to anti-EGFR therapy ) , hairy cell leukemia ( for diagnosis ) , lung adenocarcinomas ( to predict response to therapy ) , thyroid cancer ( for preoperative detection of thyroid cancer in FNA samples and prognosis in papillary thyroid carcinoma ) , or melanoma ( to predict response to BRAF kinase inhibitors ) .\\r\\n'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ">> b'neither sensitive for BRAF V600 mutations nor specific for BRAF V600E mutations , confounding accurate outcome evaluations and preventing its usefulness in selecting patient for Tafinlar therapy\\r\\n'\n",
      ">> b'not been extensively evaluated\\r\\n'\n",
      ">> b'no therapy\\r\\n'\n",
      ">> b'no evidence of heart failure\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b\"not confer the (`` `` cardioprotection ('' '' of betablockers should the arrhythmia represent early DCM\\r\\n\"\n",
      "--- forced remove SBAR\n",
      ">> b'neither atenolol nor diltiazem should be administered to cats with overt CHF , as such therapy has been shown to be either detrimental or not beneficial to short-term outcome .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'neither atenolol nor diltiazem should be administered to cats with overt CHF , as such therapy has been shown to be either detrimental or not beneficial to short-term outcome .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'neither atenolol nor diltiazem should be administered to cats with overt CHF , as such therapy has been shown to be either detrimental or not beneficial to short-term outcome .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'neither atenolol nor diltiazem should be administered to cats with overt CHF , as such therapy has been shown to be either detrimental or not beneficial to short-term outcome .\\r\\n'\n",
      ">> b'no therapy or , empirically , a badrenergic blocker or diltiazem\\r\\n'\n",
      ">> b'no therapy or , empirically , a badrenergic blocker or diltiazem\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'without obstruction , and especially when there is concurrent LA dilatation , diltiazem may be a therapeutic consideration\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'without obstruction , and especially when there is concurrent LA dilatation , diltiazem may be a therapeutic consideration\\r\\n'\n",
      ">> b'An otolarnolgologist treated with a steroid taper and valacyclovir and the hearing loss resolved\\r\\n'\n",
      ">> b'An otolarnolgologist treated with a steroid taper and valacyclovir and the hearing loss resolved\\r\\n'\n",
      ">> b'not improving\\r\\n'\n",
      ">> b'not improving\\r\\n'\n",
      ">> b'with no improvement\\r\\n'\n",
      ">> b'no significant difference )\\r\\n'\n",
      ">> b'no significant difference )\\r\\n'\n",
      ">> b'not be treated with dapsone and was treated alternatively with minocycline 100 mg , rifampin 600 mg , and clofazimine 50 mg daily\\r\\n'\n",
      ">> b'not be treated with dapsone and was treated alternatively with minocycline 100 mg , rifampin 600 mg , and clofazimine 50 mg daily\\r\\n'\n",
      ">> b'without benefit ; skin testing to foods was negative , and CBC , differential , sedimentation rate , antinuclear antibody , and liver function testing was normal or negative\\r\\n'\n",
      ">> b'not be treated with dapsone and was treated alternatively with minocycline 100 mg , rifampin 600 mg , and clofazimine 50 mg daily\\r\\n'\n",
      ">> b'not be treated with dapsone and was treated alternatively with minocycline 100 mg , rifampin 600 mg , and clofazimine 50 mg daily\\r\\n'\n",
      ">> b'without benefit ; skin testing to foods was negative , and CBC , differential , sedimentation rate , antinuclear antibody , and liver function testing was normal or negative\\r\\n'\n",
      ">> b'not be treated with dapsone and was treated alternatively with minocycline 100 mg , rifampin 600 mg , and clofazimine 50 mg daily\\r\\n'\n",
      ">> b'not be treated with dapsone and was treated alternatively with minocycline 100 mg , rifampin 600 mg , and clofazimine 50 mg daily\\r\\n'\n",
      ">> b'without any complications\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not experience any severe side effects with G-CSF mobilization , an alternative strategy to mobilize stem cells in sickle cell trait donors and to mobilize autologous stem cells from SCD patients may be the use of plerixafor , as safely demonstrated in gene therapy studies -LSB- 29 -RSB- .\\r\\n'\n",
      ">> b'not recommended because antimicrobials administered to calves with diarrhea should have both local and systemic effects , and orally administered gentamicin is poorly absorbed\\r\\n'\n",
      ">> b'not recommended because antimicrobials administered to calves with diarrhea should have both local and systemic effects , and orally administered gentamicin is poorly absorbed\\r\\n'\n",
      ">> b'not \\xce\\xb2-lactamase resistant\\r\\n'\n",
      ">> b'not , and will not , unveil drug and human biology interactions\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not remain a potential threat which it uses to pose earlier\\r\\n'\n",
      ">> b'no randomized control trials have been done -LSB- 94 -RSB- .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not differentiate into adipocytes as they normally do under the sole influence of MDI\\r\\n'\n",
      ">> b'not have received topical therapeutic modality apart from petrolatum for the last 4 weeks or systemic therapy for the last 8 weeks .\\r\\n'\n",
      ">> b'not have received topical therapeutic modality apart from petrolatum for the last 4 weeks or systemic therapy for the last 8 weeks .\\r\\n'\n",
      ">> b'without erythromycin\\r\\n'\n",
      ">> b'without erythromycin\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not be used because of the danger of producing drug resistance against an antibiotic that has special therapeutic value\\r\\n'\n",
      ">> b'no corresponding improvement in cognitive performance ( ADAS-Cog score ; Sano et al. , 2011 )\\r\\n'\n",
      ">> b'not shown )\\r\\n'\n",
      ">> b'no vaccine for RSV and the only FDA-approved therapy is passive prophylaxis with the monoclonal antibody palivizumab ( Synagis ) -LSB- 5 -RSB-\\r\\n'\n",
      ">> b'not prevented .\\r\\n'\n",
      ">> b'not prevented .\\r\\n'\n",
      ">> b'not recommended for use in rabbits\\r\\n'\n",
      ">> b'not recommended for use in rabbits\\r\\n'\n",
      ">> b'without an apparent effect on dimerization , glycine to leucine point mutations in the transmembrane domain had a profound effect on the growth phenotype produced by CEACAM1-4S .\\r\\n'\n",
      ">> b'no clinical response was observed\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b\"not identify the risk factors of treatment failure ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b\"not identify the risk factors of treatment failure ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b\"not identify the risk factors of treatment failure ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b\"not identify the risk factors of treatment failure ,\n",
      ">> b'without any complications\\r\\n'\n",
      ">> b'rather than the more conventional piperacillin-tazobactam , ceftazidime or ciprofloxacin with or without gentamicin .\\r\\n'\n",
      ">> b'not undergone formal assessment in clinical trials .\\r\\n'\n",
      ">> b'not undergone formal assessment in clinical trials .\\r\\n'\n",
      ">> b'Due to febrile neutropenia , the patient was treated with cefuroxime and later with piperacillin-tazobactam until day 6 of induction ( day 8 of hospitalization ) ; fever timely resolved\\r\\n'\n",
      ">> b'Due to febrile neutropenia , the patient was treated with cefuroxime and later with piperacillin-tazobactam until day 6 of induction ( day 8 of hospitalization ) ; fever timely resolved\\r\\n'\n",
      ">> b'noted ( progressive clinical or radiologic findings ) , granulocyte transfusions were given .\\r\\n'\n",
      ">> b'not EGDe , and incubated at 37uC and 200 rpm for 1 h\\r\\n'\n",
      ">> b'ruled out ( A-II ) .\\r\\n'\n",
      ">> b'ruled out ( A-II ) .\\r\\n'\n",
      ">> b'not find reports of Crimean Congo hemorrhagic fever , tick borne encephalitis , severe fever with thrombocytopenia syndrome , Q fever , brucellosis or other rickettsial diseases in adventure travelers , the potential exposure to ticks and wildlife places them at risk for these or other vector-borne diseases .\\r\\n'\n",
      ">> b'no gender bias and about 75 % of dogs respond to prednisone therapy ( 0.33 to 1 1 mg/kg q12h ) .\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not susceptible to the synergistic activity of combined amphotericin B and flucytosine therapy\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not susceptible to the synergistic activity of combined amphotericin B and flucytosine therapy\n",
      ">> b'not isolated\\r\\n'\n",
      ">> b'not treated with ribavirin , no determination can be made in this study concerning potentiation of these laboratory abnormalities by IV ribavirin ( Lee , 1991 ; Mustonen et al. , 1994a )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not be made for all variables that may influence disease severity ( i.e. , demographics of subjects , hantavirus strains , exposure dose that may be influenced by yearly infected rodent population , treatment variability , vaccination status )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'Hypotension ( defined as systolic blood pressure less than 90 mm of mercury ) , present in two individuals when IV ribavirin was initiated , was managed with fluids and vasopressors , and resolved\\r\\n'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ">> b'without ribavirin ( 25 \\xce\\xbcg/mL ) and OMT ( 50 \\xce\\xbcg/mL ) , and simultaneously treated with or without TLR3 activator ( polyI : C , 100 ng/mL ) , TLR4 activator LPS-B5 ( 1 \\xce\\xbcg/mL ) , TLR7/8 activator R-848 ( 10 \\xce\\xbcg/mL ) , PI-3K / Akt activator ( IGF-1 , 100 ng/mL ) , ERK activator ( EGF , 100 ng/mL ) , p38/JNK activator ( Anisomycin , 10 \\xce\\xbcM ) , and NF-\\xce\\xbaB activator ( PMA , 1 \\xce\\xbcg/mL )\\r\\n'\n",
      ">> b'without ribavirin ( 25 \\xce\\xbcg/mL ) and OMT ( 50 \\xce\\xbcg/mL ) , and simultaneously treated with or without TLR3 activator ( polyI : C , 100 ng/mL ) , TLR4 activator LPS-B5 ( 1 \\xce\\xbcg/mL ) , TLR7/8 activator R-848 ( 10 \\xce\\xbcg/mL ) , PI-3K / Akt activator ( IGF-1 , 100 ng/mL ) , ERK activator ( EGF , 100 ng/mL ) , p38/JNK activator ( Anisomycin , 10 \\xce\\xbcM ) , and NF-\\xce\\xbaB activator ( PMA , 1 \\xce\\xbcg/mL )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not treated with any drugs ; in the positive control ( PC ) and OMT-treated groups , MDCK cells were infected with IAV ( ST169 ) and treated with ribavirin ( 25 \\xce\\xbcg/mL ) and OMT ( 400 , 200 , 100 and 50 \\xce\\xbcg/mL , respectively ) , MOI = (NP-TMP 0.001 , the incubation time was 48 h\\r\\n'\n",
      ">> b'without ribavirin ( 25 \\xc2\\xb5g/mL ) and OMT ( 50 \\xc2\\xb5g/mL ) , and simultaneously treated with or without TLR3 activator ( polyI : C , 100 ng/mL ) , TLR4 activator LPS-B5 ( 1 \\xc2\\xb5g/mL ) , TLR7/8 activator R-848 ( 10 \\xc2\\xb5g/mL ) , PI-3K / Akt activator ( IGF-1 , 100 ng/mL ) , ERK activator ( EGF , 100 ng/mL ) , p38/JNK activator ( Anisomycin , 10 \\xc2\\xb5M ) , and NF-\\xce\\xbaB activator ( PMA , 1 \\xc2\\xb5g/mL )\\r\\n'\n",
      ">> b'without ribavirin ( 25 \\xc2\\xb5g/mL ) and OMT ( 50 \\xc2\\xb5g/mL ) , and simultaneously treated with or without TLR3 activator ( polyI : C , 100 ng/mL ) , TLR4 activator LPS-B5 ( 1 \\xc2\\xb5g/mL ) , TLR7/8 activator R-848 ( 10 \\xc2\\xb5g/mL ) , PI-3K / Akt activator ( IGF-1 , 100 ng/mL ) , ERK activator ( EGF , 100 ng/mL ) , p38/JNK activator ( Anisomycin , 10 \\xc2\\xb5M ) , and NF-\\xce\\xbaB activator ( PMA , 1 \\xc2\\xb5g/mL )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not modified by the angiotensin receptor blocker , losartan -LSB- 79 -RSB- , suggesting that the effects of enhancing the Ang 1-7 mas axis may be beneficial , even in the setting of conventional RAS blockade\\r\\n'\n",
      ">> b'not available from these cases .\\r\\n'\n",
      ">> b'not available from these cases .\\r\\n'\n",
      ">> b'not recur during the follow-up period ( 2-4 years )\\r\\n'\n",
      ">> b'not effective -LSB- 37 -RSB- .\\r\\n'\n",
      ">> b'not effective -LSB- 37 -RSB- .\\r\\n'\n",
      ">> b'For therapeutic use , zeomycin could be replaced with a codon-optimized CpG free\\r\\n'\n",
      ">> b'not effective enough for some HCV genotypes and shows serious side effects , such as influenza-like symptoms , mental health problems , and hematological abnormalities\\r\\n'\n",
      ">> b'not demonstrate benefit\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not any better ; the plasma levels of SARS-CoV mRNA were increased in the second and third weeks of illness compared to those who received placebo\\r\\n'\n",
      ">> b\"not effective in treating SARS patients in Liu et al 's report\\r\\n\"\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not significantly affect viral titers or disease severity ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'novirus infections ,\n",
      ">> b'not receive prescribed antibiotics according to recommended guidelines\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'no definitive cure ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'no definitive cure ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'no definitive cure ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'no definitive cure ,\n",
      "--- forced remove SBAR\n",
      ">> b\"not stated ( 2 ) Control group ( n = (NP-TMP 72 ) (`` `` All the patients were given routine treatments , including managing blood pressure , maintaining the balance of hydrolyte and electrolure , reducing intracranial pressure by dehydration , and venous injection of citicoline ('' '' The individual components delivered are listed in Table 3\\r\\n\"\n",
      "--- forced remove SBAR\n",
      ">> b\"not stated ( 2 ) Control group ( n = (NP-TMP 72 ) (`` `` All the patients were given routine treatments , including managing blood pressure , maintaining the balance of hydrolyte and electrolure , reducing intracranial pressure by dehydration , and venous injection of citicoline ('' '' The individual components delivered are listed in Table 3\\r\\n\"\n",
      ">> b'not inferior to its seven-day counterpart in terms of therapeutic effects -LSB- 137 -RSB- .\\r\\n'\n",
      ">> b'not inferior to its seven-day counterpart in terms of therapeutic effects -LSB- 137 -RSB- .\\r\\n'\n",
      ">> b'notherapy are not inferior to those of the ceftriaxone and levofloxacin combination therapy -LSB- 150 -RSB-\\r\\n'\n",
      ">> b'notherapy are not inferior to those of the ceftriaxone and levofloxacin combination therapy -LSB- 150 -RSB-\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'no significant drug-drug interactions between nelfinavir or indinavir and mefloquine 116 ; ( 2 ) ritonavir has minimal effects on mefloquine pharmacokinetics , whereas mefloquine suppresses ritonavir plasma levels (NP-TMP 117 ; and ( 3 ) atovaquone increases serum zidovudine ( AZT ) levels by approximately 30 % ,\n",
      ">> b'not , apparently , in the HIV-infected population ) have left isoniazid the prophylactic agent of choice\\r\\n'\n",
      ">> b'not , apparently , in the HIV-infected population ) have left isoniazid the prophylactic agent of choice\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'with no clinical improvement and persistence of low-grade fever after 5 days , when rifampin was changed to linezolid\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'with no clinical improvement and persistence of low-grade fever after 5 days , when rifampin was changed to linezolid\\r\\n'\n",
      ">> b'ruled out by lumbar puncture )\\r\\n'\n",
      ">> b'ruled out by lumbar puncture )\\r\\n'\n",
      ">> b'ruled out by lumbar puncture )\\r\\n'\n",
      ">> b'ruled out by lumbar puncture )\\r\\n'\n",
      ">> b'refused antiviral therapy with entecavir in 2009 and was diagnosed in February 2016 with HCC with extrahepatic extension\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'without ribavirin in HCV genotype 1b infected patients with compensated cirrhosis Anca Leu\\xc8\\x99tean 1 , Victoria Aram\\xc4\\x83 1 , 2 The regimen approved for the therapy of HCV Child Pugh A cirrhosis , contained at the beginning different combinations of direct acting antivirals and ribavirin\\r\\n'\n",
      ">> b'no clinical improvement\\r\\n'\n",
      ">> b'not been identified\\r\\n'\n",
      ">> b'no acids , arginine , cysteine , and tryptophan , a number of different tRNAs must mediate UGA suppression\\r\\n'\n",
      ">> b'no acids , arginine , cysteine , and tryptophan , a number of different tRNAs must mediate UGA suppression\\r\\n'\n",
      ">> b'no acids , arginine , cysteine , and tryptophan , a number of different tRNAs must mediate UGA suppression\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'nonsense suppressor tRNAs ( mutant tRNAs whose anticodons pair with termination codons ,\n",
      ">> b'with nonessential amino acids , sodium pyruvate , Hepes , L-glutamine , 2-mercaptoethanol , and penicillinstreptomycin -LSB- Gibco -RSB- ) with or without recombinant IL-27 ( 20 ng/ml ; R&D Systems ) or recombinant IFN\\xce\\xb2 ( 1,000 U/ml , carrier-free ; PBL Assay Science ) for 12 h at 37 \\xc2\\xb0C .\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'no strong evidence that any of the existing anti-influenza drugs , including oseltamivir , were beneficial in treating the encephalopathy\\r\\n'\n",
      ">> b'not advised ; the preferred drug in treating human cases , metronidazole , may exacerbate toxicosis in guinea pigs ( Cleary et al. , 1998 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not alter patient mortality ,\n",
      ">> b'not routine in clinical practice\\r\\n'\n",
      ">> b'not high (NP-TMP -LSB- 32 -RSB-\\r\\n'\n",
      ">> b'no effect of increased vancomycin MICs of isolates on patient outcome\\r\\n'\n",
      ">> b'not effective in vivo ( 10 ) , except for posaconazole , which shows some efficacy both experimentally and in patients as second-line therapy ( 11 ) ( 12 ) ( 13 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not only for HIV , as detailed in the following subsection ,\n",
      ">> b'not imply effectiveness of cidofovir administered after progression to respiratory failure\\r\\n'\n",
      ">> b'without the use of the active technologies or enhancers described in the following paragraphs\\r\\n'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ">> b'without the use of the active technologies or enhancers described in the following paragraphs\\r\\n'\n",
      ">> b'without the use of the active technologies or enhancers described in the following paragraphs\\r\\n'\n",
      ">> b'without the use of the active technologies or enhancers described in the following paragraphs\\r\\n'\n",
      ">> b'without the use of the active technologies or enhancers described in the following paragraphs\\r\\n'\n",
      ">> b'without the use of the active technologies or enhancers described in the following paragraphs\\r\\n'\n",
      ">> b'without the use of the active technologies or enhancers described in the following paragraphs\\r\\n'\n",
      ">> b'not treated with trypsin ( Fig\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not responding to oral or inhaled therapy or when drug delivery by these routes is not feasible\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'without obvious effects on IgG levels ) suggests that antibody-independent functions of B cells likely contribute to the observed therapeutic effect .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not when Es was implanted (NP-TMP 3 days after MPTP\\r\\n'\n",
      ">> b'absence of 10 \\xce\\xbcM TPCK ( NFkB blocker ) , 100 nM RO-32-0432 ( pan-PKC inhibitor ) , 10 \\xce\\xbcM chloroquine , 10 \\xce\\xbcM pyramethamine , or CD3/CD28 antibodies\\r\\n'\n",
      ">> b'without treatment , in most cases without treatment the symptoms will wax and wane for many months\\r\\n'\n",
      ">> b'not require a virus-specific phosphorylation step for activation\\r\\n'\n",
      ">> b'not require a virus-specific phosphorylation step for activation\\r\\n'\n",
      ">> b'not require a virus-specific phosphorylation step for activation\\r\\n'\n",
      ">> b'rather than use of lysine as a treatment during acute or recrudescent episodes\\r\\n'\n",
      ">> b'The cats were administered paromomycin for 5 days , and the diarrhea resolved\\r\\n'\n",
      ">> b'not treated with trypsin\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not treat virus particles with trypsin after incubation with the gizzard fluid to determine whether it might contain a protease that activates HA\\r\\n'\n",
      ">> b'absence of doxorubicin ( 324380 , Calbiochem ) for 24 h and mixed with Cell-Titer Glo ( G7572 , Promega ) for 10 min\\r\\n'\n",
      ">> b'without doxorubicin for 24 h\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no Src inhibitors successfully suppresses tumors in cancer patients when used alone , possibly because there is no suitable biomarker to monitor Src activation in tumor tissues or because the treatment triggers alternative routes for resistance to Src inhibition ( Zhang and Yu , 2012 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'absence of staurosporine ( STS ; Figure 1A ) , a pan kinase inhibitor that wildly suppress many kinases at low dose ( Meggio et al. , 1995 )\\r\\n'\n",
      ">> b\"not use another , the so-called (`` `` pyrimidine salvage pathway . ('' ''\\r\\n\"\n",
      "--- forced remove SBAR\n",
      ">> b'not provide a clear mortality benefit , the use of dexamethasone showed a trend towards fewer neurologic sequelae and those who received phenytoin experienced no seizures\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not provide a clear mortality benefit , the use of dexamethasone showed a trend towards fewer neurologic sequelae and those who received phenytoin experienced no seizures\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not provide a clear mortality benefit , the use of dexamethasone showed a trend towards fewer neurologic sequelae and those who received phenytoin experienced no seizures\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not provide a clear mortality benefit , the use of dexamethasone showed a trend towards fewer neurologic sequelae and those who received phenytoin experienced no seizures\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not provide a clear mortality benefit , the use of dexamethasone showed a trend towards fewer neurologic sequelae and those who received phenytoin experienced no seizures\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not provide a clear mortality benefit , the use of dexamethasone showed a trend towards fewer neurologic sequelae and those who received phenytoin experienced no seizures\\r\\n'\n",
      ">> b'no significant difference in RSV pneumonia ; the study prematurely stopped due to slow accrual\\r\\n'\n",
      ">> b'no other therapy\\r\\n'\n",
      ">> b'not treated with 500 ng/ml doxycycline ( Dox ) for 72 h to induce transgene expression or OARD1 knock-down before seeding onto 96 well-plates\\r\\n'\n",
      ">> b'not treated with 100 ng/ml doxycycline to induce HA-TARG1 expression for 48 h\\r\\n'\n",
      ">> b'not treated with 500 ng/ml doxycycline ( - / + Dox ) for 72 h to induce transgene expression or OARD1 knock-down before seeding the cells in 6-well plates in cell culture medium - / + doxycycline\\r\\n'\n",
      ">> b'not common , central vestibular signs have been reported in cats after chronic high-dose therapy with metronidazole\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not been reported in cats when standard clinical doses have been prescribed\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no vestibular abnormalities were seen when these drugs solutions were administered at 0.2 per cent and 0.3 per cent concentrations , respectively\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not clear at this point how all of these control sequences interact with the suppressing glutamine tRNA ( Yoshinaka et al. , 1985a , b ; Kuchino et al. , 1987 ) and/or with the ribosome complex to facilitate the readthrough event .\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'notion that a cellular glutamine tRNA is responsible for the readthrough of the nonsense codon UAG ( Kuchino et a / .\\r\\n'\n",
      ">> b'no effective therapy for VHF infection other than ribavirin for patients with Lassa fever or New World arenavirus infection ; treatment for filovirus infection remains supportive .\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'no antiviral drugs approved by the US Food and Drug Administration for use in the setting of VHF infection -LSB- 3 -RSB- ;\n",
      ">> b'not diagnosed with Lassa fever until day 13 and died 3 days later despite the initiation of ribavirin therapy -LSB- 23 -RSB-\\r\\n'\n",
      ">> b'not active against the latent form of EBV found in PTLD\\r\\n'\n",
      ">> b'not active against the latent form of EBV found in PTLD\\r\\n'\n",
      ">> b'not exceeding 7.5 to 15 mg per week )\\r\\n'\n",
      ">> b'not Food and Drug Administration-approved for use in solid organ transplant recipients ) include foscarnet , cidofovir , and leflunomide ; these are reserved for treatment of antiviral resistance\\r\\n'\n",
      ">> b'not Food and Drug Administration-approved for use in solid organ transplant recipients ) include foscarnet , cidofovir , and leflunomide ; these are reserved for treatment of antiviral resistance\\r\\n'\n",
      ">> b'not Food and Drug Administration-approved for use in solid organ transplant recipients ) include foscarnet , cidofovir , and leflunomide ; these are reserved for treatment of antiviral resistance\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not recommended because it treats influenza A only and increasing rates of resistance have been seen in influenza A\\r\\n'\n",
      ">> b'not been proven\\r\\n'\n",
      ">> b'without evoking inflammatory mediators -LSB- 44 -RSB-\\r\\n'\n",
      ">> b'without evoking inflammatory mediators -LSB- 44 -RSB-\\r\\n'\n",
      ">> b'not been confirmed to be effective , and the effects of steroids administered to the most severe cases evolving to ARDS remain anecdotal .\\r\\n'\n",
      ">> b'not been confirmed to be effective , and the effects of steroids administered to the most severe cases evolving to ARDS remain anecdotal .\\r\\n'\n",
      ">> b'absence of bacteriological evidence and given the favorable clinical course , antibiotic therapy was reduced to ceftriaxone alone for 10 days\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no ) benzoyl ester 4 was performed\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'The shedding of eggs in the stools can be intermittent , so it is always appropriate to administer a broad-spectrum dewormer ( eg , fenbendazole ; 50 mg/kg by mouth daily for 3 days ) to any patient with diarrhea , even if a fecal flotation is negative\\r\\n'\n",
      ">> b'absence of PLZF expression ( 24 h tetracycline withdrawal ) and RNA samples analyzed for ISG expression\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not receive cytotoxic agents that could have diminished thymic epithelial function ( 31 )\\r\\n'\n",
      ">> b'no therapy with isavuconazole or voriconazole is the preferred firstline treatment and therapeutic drug monitoring should be utilized to ensure adequacy of dosing -LSB- 55 -RSB-\\r\\n'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ">> b'no therapy with isavuconazole or voriconazole is the preferred firstline treatment and therapeutic drug monitoring should be utilized to ensure adequacy of dosing -LSB- 55 -RSB-\\r\\n'\n",
      ">> b'no therapy with isavuconazole or voriconazole is the preferred firstline treatment and therapeutic drug monitoring should be utilized to ensure adequacy of dosing -LSB- 55 -RSB-\\r\\n'\n",
      ">> b'no therapy with isavuconazole or voriconazole is the preferred firstline treatment and therapeutic drug monitoring should be utilized to ensure adequacy of dosing -LSB- 55 -RSB-\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not replicated when a randomized controlled trial design as applied -LSB- 82 -RSB-\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'without taking bacterial culture results into account\\r\\n'\n",
      "--- remove CP\n",
      ">> b'Multiagent chemotherapy ( prednisone , vincristine , cyclophosphamide ) has been used to treat colonic lymphoma ,\n",
      "--- remove CP\n",
      ">> b'Multiagent chemotherapy ( prednisone , vincristine , cyclophosphamide ) has been used to treat colonic lymphoma ,\n",
      ">> b'not inhibit ALV-A infection -LSB- 19 -RSB-\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not found in NMRI mice inoculated intraperitoneally with MHV-3 , even among mice treated with prednisolone ( Galanti et al\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'The kittens ( six per group ) were treated as follows : ribavirin only ( 5.5 mg kg - I bodyweight , intravenously ) ; ribavirin incorporated into liposomes ( 5-0 mg kg -1 bodyweight , intravenously ) along with a small amount ( approximately 0.5 mg kg -1 bodyweight , intravenously ) or unincorporated or free\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'Significant differences in survival rate after FIPV challenge exposure were not observed between untreated kittens and those treated with either free\\r\\n'\n",
      ">> b'not effectively treat cats infected with FIPV or protect them against virus-induced mortality\\r\\n'\n",
      ">> b'not released by cells treated with doxorubicin ( a proapoptotic drug ) or cells transfected with NS3 wild type PRF or NS3 12del483A PRF ( mutant and nontoxic PRF ) -LSB- 94 -RSB-\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not been identified , certain strategies have been proposed , including use of aerosolized ribavirin ( 155 , 156 ) , RSV antibodies ( i.e. , passive immunization with high RSV-titered IVIG or RSV immunoglobulin ) in combination with aerosolized ribavirin ( 137 , 157 ) , and RSV monoclonal antibody ( 158 )\\r\\n'\n",
      ">> b'no benefit has been reported from routinely administering ganciclovir prophylaxis to all HSCT recipients at > (NP-TMP 100 days after HSCT ( i.e. , during phase III )\\r\\n'\n",
      ">> b'not recommended because of lack of efficacy ( 107,108 ) ( DII ) .\\r\\n'\n",
      "--- remove CP\n",
      ">> b'nother antibiotic ,\n",
      "--- remove CP\n",
      ">> b'nother antibiotic ,\n",
      ">> b'not with this SlOO extract\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'noting that not all alternative agents are equivalent in efficacy to preferred first-line therapies , as illustrated in recent US shortages of norepinephrine , 30\n",
      ">> b'not impair responsiveness to corticosteroids\\r\\n'\n",
      ">> b'not administered in those with other respiratory viruses\\r\\n'\n",
      ">> b'not administered in those with other respiratory viruses\\r\\n'\n",
      ">> b'not administered in those with other respiratory viruses\\r\\n'\n",
      ">> b'not administered in those with other respiratory viruses\\r\\n'\n",
      ">> b'We excluded\\r\\n'\n",
      ">> b'We excluded\\r\\n'\n",
      ">> b'We excluded\\r\\n'\n",
      ">> b'no episodes of cerebral infarction and no cerebral haemorrhage\\r\\n'\n",
      ">> b'no episodes of cerebral infarction and no cerebral haemorrhage\\r\\n'\n",
      ">> b'not recommended in patients with hepatitis C virus infection and renal dysfunction ( Clcr < 50 mL/minute ) .\\r\\n'\n",
      ">> b'rather than 7 days of cytarabine at 100-200 mg/m (NP-TMP 2 / dose were used ; moreover , HOVON / SAKK post remission therapy often included amsacrine\\r\\n'\n",
      ">> b'rather than 7 days of cytarabine at 100-200 mg/m (NP-TMP 2 / dose were used ; moreover , HOVON / SAKK post remission therapy often included amsacrine\\r\\n'\n",
      ">> b'rather than 7 days of cytarabine at 100-200 mg/m (NP-TMP 2 / dose were used ; moreover , HOVON / SAKK post remission therapy often included amsacrine\\r\\n'\n",
      ">> b'rather than 7 days of cytarabine at 100-200 mg/m (NP-TMP 2 / dose were used ; moreover , HOVON / SAKK post remission therapy often included amsacrine\\r\\n'\n",
      ">> b'rather than 7 days of cytarabine at 100-200 mg/m (NP-TMP 2 / dose were used ; moreover , HOVON / SAKK post remission therapy often included amsacrine\\r\\n'\n",
      ">> b'rather than 7 days of cytarabine at 100-200 mg/m (NP-TMP 2 / dose were used ; moreover , HOVON / SAKK post remission therapy often included amsacrine\\r\\n'\n",
      ">> b'not been reported\\r\\n'\n",
      ">> b'not been reported\\r\\n'\n",
      ">> b'not been reported\\r\\n'\n",
      "--- remove CP\n",
      ">> b'no pharmaceutic agent is considered completely effective in treating cryptosporidiosis ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not improve the consistency or reduce the production of soft faeces ,\n",
      ">> b'no Enzyme Inc. , Japan ) at 45 \\xe2\\x80\\xa2 C for 4 h at pH 8.5-9.0 and then heated at 90 \\xe2\\x80\\xa2 C for 5 min for enzyme deactivation\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'without fast breathing be treated as outpatients without antibiotics ; those who have fast breathing ( nonsevere pneumonia ) be treated at home with oral co-trimoxazole or amoxicillin for 5 days ; and those who have lower chest indrawing ( severe pneumonia ) and general danger signs ( very severe disease ) be referred to hospital and treated with parenteral ampicillin/penicillin .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'without fast breathing be treated as outpatients without antibiotics ; those who have fast breathing ( nonsevere pneumonia ) be treated at home with oral co-trimoxazole or amoxicillin for 5 days ; and those who have lower chest indrawing ( severe pneumonia ) and general danger signs ( very severe disease ) be referred to hospital and treated with parenteral ampicillin/penicillin .\\r\\n'\n",
      ">> b'not suspected\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not receiving immunosuppressants as demonstrated in studies involving anti-TNF drugs -LSB- 143 -RSB- , as well as rituximab , where a correlation between the presence of ADAb , weak B cell depletion and clinical outcomes has been noted -LSB- 144 -RSB-\\r\\n'\n",
      ">> b'without reducing viral titers ( Costa et al. , 2017 )\\r\\n'\n",
      ">> b'not associated with HZ .\\r\\n'\n",
      ">> b'not associated with HZ .\\r\\n'\n",
      ">> b'not associated with HZ .\\r\\n'\n",
      ">> b'with no recurrence of fever thereafter\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'no significant clinical improvement , she was administered Inj methylprednisolone 30 mg/kg for 3 days , following which ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not reduce the treatment resistance ,\n",
      ">> b'not showing any response to this therapy\\r\\n'\n",
      ">> b'not showing any response to this therapy\\r\\n'\n",
      ">> b'not shown )\\r\\n'\n",
      ">> b'not internalized virus\\r\\n'\n",
      ">> b'without corticosteroid use ( 135 ) ( 136 ) ( 137 )\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'without acute side effects , and it is therefore possible that a therapeutic agent based on the lipophilic glycopeptide structure described in this study could become a useful therapeutic agent\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'without acute side effects , and it is therefore possible that a therapeutic agent based on the lipophilic glycopeptide structure described in this study could become a useful therapeutic agent\\r\\n'\n",
      ">> b'not lead to the alternative activation of these cells -LSB- 46 -RSB- -LSB- 47 -RSB- -LSB- 48 -RSB-\\r\\n'\n",
      ">> b'without corticosteroids , has been reported in Slovenian sarcoidosis patients\\r\\n'\n",
      ">> b'without corticosteroids , has been reported in Slovenian sarcoidosis patients\\r\\n'\n",
      ">> b'Among the 35 patients with IA , 17 patients were free\\r\\n'\n",
      ">> b'Among the 35 patients with IA , 17 patients were free\\r\\n'\n",
      ">> b'Among the 35 patients with IA , 17 patients were free\\r\\n'\n",
      ">> b'no response to treatment , NCD cases were treated with 2 mg/kg gentamicin IM ( Genta-ject \\xc2\\xae 10 % , Dopharma , Raamsdonksveer , Nederland )\\r\\n'\n",
      "--- NP with that\n",
      ">> b\"without differential cell count , influenza antigen or culture , diagnostic tests for respiratory organisms other than influenza ( respiratory syncytial virus , adenovirus , legionella ) , streptococcal throat screen , sputum culture or Gram stain , Gram stain for other respiratory specimens , blood cultures ) ; d ) requests for diagnostic imaging ( chest X-ray , chest computerized tomography , any respiratory sinus imaging ) ; and e ) new prescriptions ( none similar in the last 90 days ) , selected from the VA national formulary and grouped into the following parameters by expert consensus : cough remedies ( from VA national formulary ( VANF ) drug classes RE-200 , -301 , -302 , -502 , -503 , -507 , -508 , -513 , -516 , or codeine ) , (`` `` other cold remedies ('' '' ( from VANF CN-900 , MS-102 , NT-100 , -200 , -400 , -900 , RE-99 , -501 ) ; antiemetics ( from VANF GA-700 ) , antidiarrheals ( from VANF GA-400 ) , influenza-targeting antivirals ( neuraminidase inhibitors or adamantanes ) , and alternative groupings of antibacterials ( i : 33 antibiotics that could be prescribed for ARI ( from VANF AM-051 , -052 , -053 , -101 , -102 , -103 , -200 , -250 , -300 , -650 and -900 ) ; ii : 11 antibiotics commonly prescribed for ARI ( clarithromycin , erythromycin , azithromycin , clindamycin , amoxicillin/clavulanate , amoxicillin , penicillin V , gatifloxacin , levofloxacin , cefaclor , tetracycline and doxycycline ) ; iii : the three antibiotics most commonly associated with an encounter ascribed an ICD-9 code from the ESSENCE (`` `` respiratory ('' '' grouping at both sites ( amoxicillin/clavulanate , azithromycin and clarithromycin )\\r\\n\"\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- NP with that\n",
      ">> b\"without differential cell count , influenza antigen or culture , diagnostic tests for respiratory organisms other than influenza ( respiratory syncytial virus , adenovirus , legionella ) , streptococcal throat screen , sputum culture or Gram stain , Gram stain for other respiratory specimens , blood cultures ) ; d ) requests for diagnostic imaging ( chest X-ray , chest computerized tomography , any respiratory sinus imaging ) ; and e ) new prescriptions ( none similar in the last 90 days ) , selected from the VA national formulary and grouped into the following parameters by expert consensus : cough remedies ( from VA national formulary ( VANF ) drug classes RE-200 , -301 , -302 , -502 , -503 , -507 , -508 , -513 , -516 , or codeine ) , (`` `` other cold remedies ('' '' ( from VANF CN-900 , MS-102 , NT-100 , -200 , -400 , -900 , RE-99 , -501 ) ; antiemetics ( from VANF GA-700 ) , antidiarrheals ( from VANF GA-400 ) , influenza-targeting antivirals ( neuraminidase inhibitors or adamantanes ) , and alternative groupings of antibacterials ( i : 33 antibiotics that could be prescribed for ARI ( from VANF AM-051 , -052 , -053 , -101 , -102 , -103 , -200 , -250 , -300 , -650 and -900 ) ; ii : 11 antibiotics commonly prescribed for ARI ( clarithromycin , erythromycin , azithromycin , clindamycin , amoxicillin/clavulanate , amoxicillin , penicillin V , gatifloxacin , levofloxacin , cefaclor , tetracycline and doxycycline ) ; iii : the three antibiotics most commonly associated with an encounter ascribed an ICD-9 code from the ESSENCE (`` `` respiratory ('' '' grouping at both sites ( amoxicillin/clavulanate , azithromycin and clarithromycin )\\r\\n\"\n",
      "--- NP with that\n",
      ">> b\"without differential cell count , influenza antigen or culture , diagnostic tests for respiratory organisms other than influenza ( respiratory syncytial virus , adenovirus , legionella ) , streptococcal throat screen , sputum culture or Gram stain , Gram stain for other respiratory specimens , blood cultures ) ; d ) requests for diagnostic imaging ( chest X-ray , chest computerized tomography , any respiratory sinus imaging ) ; and e ) new prescriptions ( none similar in the last 90 days ) , selected from the VA national formulary and grouped into the following parameters by expert consensus : cough remedies ( from VA national formulary ( VANF ) drug classes RE-200 , -301 , -302 , -502 , -503 , -507 , -508 , -513 , -516 , or codeine ) , (`` `` other cold remedies ('' '' ( from VANF CN-900 , MS-102 , NT-100 , -200 , -400 , -900 , RE-99 , -501 ) ; antiemetics ( from VANF GA-700 ) , antidiarrheals ( from VANF GA-400 ) , influenza-targeting antivirals ( neuraminidase inhibitors or adamantanes ) , and alternative groupings of antibacterials ( i : 33 antibiotics that could be prescribed for ARI ( from VANF AM-051 , -052 , -053 , -101 , -102 , -103 , -200 , -250 , -300 , -650 and -900 ) ; ii : 11 antibiotics commonly prescribed for ARI ( clarithromycin , erythromycin , azithromycin , clindamycin , amoxicillin/clavulanate , amoxicillin , penicillin V , gatifloxacin , levofloxacin , cefaclor , tetracycline and doxycycline ) ; iii : the three antibiotics most commonly associated with an encounter ascribed an ICD-9 code from the ESSENCE (`` `` respiratory ('' '' grouping at both sites ( amoxicillin/clavulanate , azithromycin and clarithromycin )\\r\\n\"\n",
      "--- NP with that\n",
      ">> b\"without differential cell count , influenza antigen or culture , diagnostic tests for respiratory organisms other than influenza ( respiratory syncytial virus , adenovirus , legionella ) , streptococcal throat screen , sputum culture or Gram stain , Gram stain for other respiratory specimens , blood cultures ) ; d ) requests for diagnostic imaging ( chest X-ray , chest computerized tomography , any respiratory sinus imaging ) ; and e ) new prescriptions ( none similar in the last 90 days ) , selected from the VA national formulary and grouped into the following parameters by expert consensus : cough remedies ( from VA national formulary ( VANF ) drug classes RE-200 , -301 , -302 , -502 , -503 , -507 , -508 , -513 , -516 , or codeine ) , (`` `` other cold remedies ('' '' ( from VANF CN-900 , MS-102 , NT-100 , -200 , -400 , -900 , RE-99 , -501 ) ; antiemetics ( from VANF GA-700 ) , antidiarrheals ( from VANF GA-400 ) , influenza-targeting antivirals ( neuraminidase inhibitors or adamantanes ) , and alternative groupings of antibacterials ( i : 33 antibiotics that could be prescribed for ARI ( from VANF AM-051 , -052 , -053 , -101 , -102 , -103 , -200 , -250 , -300 , -650 and -900 ) ; ii : 11 antibiotics commonly prescribed for ARI ( clarithromycin , erythromycin , azithromycin , clindamycin , amoxicillin/clavulanate , amoxicillin , penicillin V , gatifloxacin , levofloxacin , cefaclor , tetracycline and doxycycline ) ; iii : the three antibiotics most commonly associated with an encounter ascribed an ICD-9 code from the ESSENCE (`` `` respiratory ('' '' grouping at both sites ( amoxicillin/clavulanate , azithromycin and clarithromycin )\\r\\n\"\n",
      "--- NP with that\n",
      ">> b\"without differential cell count , influenza antigen or culture , diagnostic tests for respiratory organisms other than influenza ( respiratory syncytial virus , adenovirus , legionella ) , streptococcal throat screen , sputum culture or Gram stain , Gram stain for other respiratory specimens , blood cultures ) ; d ) requests for diagnostic imaging ( chest X-ray , chest computerized tomography , any respiratory sinus imaging ) ; and e ) new prescriptions ( none similar in the last 90 days ) , selected from the VA national formulary and grouped into the following parameters by expert consensus : cough remedies ( from VA national formulary ( VANF ) drug classes RE-200 , -301 , -302 , -502 , -503 , -507 , -508 , -513 , -516 , or codeine ) , (`` `` other cold remedies ('' '' ( from VANF CN-900 , MS-102 , NT-100 , -200 , -400 , -900 , RE-99 , -501 ) ; antiemetics ( from VANF GA-700 ) , antidiarrheals ( from VANF GA-400 ) , influenza-targeting antivirals ( neuraminidase inhibitors or adamantanes ) , and alternative groupings of antibacterials ( i : 33 antibiotics that could be prescribed for ARI ( from VANF AM-051 , -052 , -053 , -101 , -102 , -103 , -200 , -250 , -300 , -650 and -900 ) ; ii : 11 antibiotics commonly prescribed for ARI ( clarithromycin , erythromycin , azithromycin , clindamycin , amoxicillin/clavulanate , amoxicillin , penicillin V , gatifloxacin , levofloxacin , cefaclor , tetracycline and doxycycline ) ; iii : the three antibiotics most commonly associated with an encounter ascribed an ICD-9 code from the ESSENCE (`` `` respiratory ('' '' grouping at both sites ( amoxicillin/clavulanate , azithromycin and clarithromycin )\\r\\n\"\n",
      "--- NP with that\n",
      ">> b\"without differential cell count , influenza antigen or culture , diagnostic tests for respiratory organisms other than influenza ( respiratory syncytial virus , adenovirus , legionella ) , streptococcal throat screen , sputum culture or Gram stain , Gram stain for other respiratory specimens , blood cultures ) ; d ) requests for diagnostic imaging ( chest X-ray , chest computerized tomography , any respiratory sinus imaging ) ; and e ) new prescriptions ( none similar in the last 90 days ) , selected from the VA national formulary and grouped into the following parameters by expert consensus : cough remedies ( from VA national formulary ( VANF ) drug classes RE-200 , -301 , -302 , -502 , -503 , -507 , -508 , -513 , -516 , or codeine ) , (`` `` other cold remedies ('' '' ( from VANF CN-900 , MS-102 , NT-100 , -200 , -400 , -900 , RE-99 , -501 ) ; antiemetics ( from VANF GA-700 ) , antidiarrheals ( from VANF GA-400 ) , influenza-targeting antivirals ( neuraminidase inhibitors or adamantanes ) , and alternative groupings of antibacterials ( i : 33 antibiotics that could be prescribed for ARI ( from VANF AM-051 , -052 , -053 , -101 , -102 , -103 , -200 , -250 , -300 , -650 and -900 ) ; ii : 11 antibiotics commonly prescribed for ARI ( clarithromycin , erythromycin , azithromycin , clindamycin , amoxicillin/clavulanate , amoxicillin , penicillin V , gatifloxacin , levofloxacin , cefaclor , tetracycline and doxycycline ) ; iii : the three antibiotics most commonly associated with an encounter ascribed an ICD-9 code from the ESSENCE (`` `` respiratory ('' '' grouping at both sites ( amoxicillin/clavulanate , azithromycin and clarithromycin )\\r\\n\"\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- NP with that\n",
      ">> b\"without differential cell count , influenza antigen or culture , diagnostic tests for respiratory organisms other than influenza ( respiratory syncytial virus , adenovirus , legionella ) , streptococcal throat screen , sputum culture or Gram stain , Gram stain for other respiratory specimens , blood cultures ) ; d ) requests for diagnostic imaging ( chest X-ray , chest computerized tomography , any respiratory sinus imaging ) ; and e ) new prescriptions ( none similar in the last 90 days ) , selected from the VA national formulary and grouped into the following parameters by expert consensus : cough remedies ( from VA national formulary ( VANF ) drug classes RE-200 , -301 , -302 , -502 , -503 , -507 , -508 , -513 , -516 , or codeine ) , (`` `` other cold remedies ('' '' ( from VANF CN-900 , MS-102 , NT-100 , -200 , -400 , -900 , RE-99 , -501 ) ; antiemetics ( from VANF GA-700 ) , antidiarrheals ( from VANF GA-400 ) , influenza-targeting antivirals ( neuraminidase inhibitors or adamantanes ) , and alternative groupings of antibacterials ( i : 33 antibiotics that could be prescribed for ARI ( from VANF AM-051 , -052 , -053 , -101 , -102 , -103 , -200 , -250 , -300 , -650 and -900 ) ; ii : 11 antibiotics commonly prescribed for ARI ( clarithromycin , erythromycin , azithromycin , clindamycin , amoxicillin/clavulanate , amoxicillin , penicillin V , gatifloxacin , levofloxacin , cefaclor , tetracycline and doxycycline ) ; iii : the three antibiotics most commonly associated with an encounter ascribed an ICD-9 code from the ESSENCE (`` `` respiratory ('' '' grouping at both sites ( amoxicillin/clavulanate , azithromycin and clarithromycin )\\r\\n\"\n",
      "--- NP with that\n",
      ">> b\"without differential cell count , influenza antigen or culture , diagnostic tests for respiratory organisms other than influenza ( respiratory syncytial virus , adenovirus , legionella ) , streptococcal throat screen , sputum culture or Gram stain , Gram stain for other respiratory specimens , blood cultures ) ; d ) requests for diagnostic imaging ( chest X-ray , chest computerized tomography , any respiratory sinus imaging ) ; and e ) new prescriptions ( none similar in the last 90 days ) , selected from the VA national formulary and grouped into the following parameters by expert consensus : cough remedies ( from VA national formulary ( VANF ) drug classes RE-200 , -301 , -302 , -502 , -503 , -507 , -508 , -513 , -516 , or codeine ) , (`` `` other cold remedies ('' '' ( from VANF CN-900 , MS-102 , NT-100 , -200 , -400 , -900 , RE-99 , -501 ) ; antiemetics ( from VANF GA-700 ) , antidiarrheals ( from VANF GA-400 ) , influenza-targeting antivirals ( neuraminidase inhibitors or adamantanes ) , and alternative groupings of antibacterials ( i : 33 antibiotics that could be prescribed for ARI ( from VANF AM-051 , -052 , -053 , -101 , -102 , -103 , -200 , -250 , -300 , -650 and -900 ) ; ii : 11 antibiotics commonly prescribed for ARI ( clarithromycin , erythromycin , azithromycin , clindamycin , amoxicillin/clavulanate , amoxicillin , penicillin V , gatifloxacin , levofloxacin , cefaclor , tetracycline and doxycycline ) ; iii : the three antibiotics most commonly associated with an encounter ascribed an ICD-9 code from the ESSENCE (`` `` respiratory ('' '' grouping at both sites ( amoxicillin/clavulanate , azithromycin and clarithromycin )\\r\\n\"\n",
      "--- NP with that\n",
      ">> b\"without differential cell count , influenza antigen or culture , diagnostic tests for respiratory organisms other than influenza ( respiratory syncytial virus , adenovirus , legionella ) , streptococcal throat screen , sputum culture or Gram stain , Gram stain for other respiratory specimens , blood cultures ) ; d ) requests for diagnostic imaging ( chest X-ray , chest computerized tomography , any respiratory sinus imaging ) ; and e ) new prescriptions ( none similar in the last 90 days ) , selected from the VA national formulary and grouped into the following parameters by expert consensus : cough remedies ( from VA national formulary ( VANF ) drug classes RE-200 , -301 , -302 , -502 , -503 , -507 , -508 , -513 , -516 , or codeine ) , (`` `` other cold remedies ('' '' ( from VANF CN-900 , MS-102 , NT-100 , -200 , -400 , -900 , RE-99 , -501 ) ; antiemetics ( from VANF GA-700 ) , antidiarrheals ( from VANF GA-400 ) , influenza-targeting antivirals ( neuraminidase inhibitors or adamantanes ) , and alternative groupings of antibacterials ( i : 33 antibiotics that could be prescribed for ARI ( from VANF AM-051 , -052 , -053 , -101 , -102 , -103 , -200 , -250 , -300 , -650 and -900 ) ; ii : 11 antibiotics commonly prescribed for ARI ( clarithromycin , erythromycin , azithromycin , clindamycin , amoxicillin/clavulanate , amoxicillin , penicillin V , gatifloxacin , levofloxacin , cefaclor , tetracycline and doxycycline ) ; iii : the three antibiotics most commonly associated with an encounter ascribed an ICD-9 code from the ESSENCE (`` `` respiratory ('' '' grouping at both sites ( amoxicillin/clavulanate , azithromycin and clarithromycin )\\r\\n\"\n",
      "--- NP with that\n",
      ">> b\"without differential cell count , influenza antigen or culture , diagnostic tests for respiratory organisms other than influenza ( respiratory syncytial virus , adenovirus , legionella ) , streptococcal throat screen , sputum culture or Gram stain , Gram stain for other respiratory specimens , blood cultures ) ; d ) requests for diagnostic imaging ( chest X-ray , chest computerized tomography , any respiratory sinus imaging ) ; and e ) new prescriptions ( none similar in the last 90 days ) , selected from the VA national formulary and grouped into the following parameters by expert consensus : cough remedies ( from VA national formulary ( VANF ) drug classes RE-200 , -301 , -302 , -502 , -503 , -507 , -508 , -513 , -516 , or codeine ) , (`` `` other cold remedies ('' '' ( from VANF CN-900 , MS-102 , NT-100 , -200 , -400 , -900 , RE-99 , -501 ) ; antiemetics ( from VANF GA-700 ) , antidiarrheals ( from VANF GA-400 ) , influenza-targeting antivirals ( neuraminidase inhibitors or adamantanes ) , and alternative groupings of antibacterials ( i : 33 antibiotics that could be prescribed for ARI ( from VANF AM-051 , -052 , -053 , -101 , -102 , -103 , -200 , -250 , -300 , -650 and -900 ) ; ii : 11 antibiotics commonly prescribed for ARI ( clarithromycin , erythromycin , azithromycin , clindamycin , amoxicillin/clavulanate , amoxicillin , penicillin V , gatifloxacin , levofloxacin , cefaclor , tetracycline and doxycycline ) ; iii : the three antibiotics most commonly associated with an encounter ascribed an ICD-9 code from the ESSENCE (`` `` respiratory ('' '' grouping at both sites ( amoxicillin/clavulanate , azithromycin and clarithromycin )\\r\\n\"\n",
      "--- NP with that\n",
      ">> b\"without differential cell count , influenza antigen or culture , diagnostic tests for respiratory organisms other than influenza ( respiratory syncytial virus , adenovirus , legionella ) , streptococcal throat screen , sputum culture or Gram stain , Gram stain for other respiratory specimens , blood cultures ) ; d ) requests for diagnostic imaging ( chest X-ray , chest computerized tomography , any respiratory sinus imaging ) ; and e ) new prescriptions ( none similar in the last 90 days ) , selected from the VA national formulary and grouped into the following parameters by expert consensus : cough remedies ( from VA national formulary ( VANF ) drug classes RE-200 , -301 , -302 , -502 , -503 , -507 , -508 , -513 , -516 , or codeine ) , (`` `` other cold remedies ('' '' ( from VANF CN-900 , MS-102 , NT-100 , -200 , -400 , -900 , RE-99 , -501 ) ; antiemetics ( from VANF GA-700 ) , antidiarrheals ( from VANF GA-400 ) , influenza-targeting antivirals ( neuraminidase inhibitors or adamantanes ) , and alternative groupings of antibacterials ( i : 33 antibiotics that could be prescribed for ARI ( from VANF AM-051 , -052 , -053 , -101 , -102 , -103 , -200 , -250 , -300 , -650 and -900 ) ; ii : 11 antibiotics commonly prescribed for ARI ( clarithromycin , erythromycin , azithromycin , clindamycin , amoxicillin/clavulanate , amoxicillin , penicillin V , gatifloxacin , levofloxacin , cefaclor , tetracycline and doxycycline ) ; iii : the three antibiotics most commonly associated with an encounter ascribed an ICD-9 code from the ESSENCE (`` `` respiratory ('' '' grouping at both sites ( amoxicillin/clavulanate , azithromycin and clarithromycin )\\r\\n\"\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ">> b'not well tested .\\r\\n'\n",
      ">> b'not well tested .\\r\\n'\n",
      ">> b'not well tested .\\r\\n'\n",
      ">> b'not responsive to metronidazole , prednisolone and dietary therapy , cytotoxic drugs may be considered\\r\\n'\n",
      ">> b'not responsive to metronidazole , prednisolone and dietary therapy , cytotoxic drugs may be considered\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'note that the first-generation imidizoquinoline imiquimod is licensed as an antiviral as well as an anticancer topical therapy ( Aldara \\xc2\\xae ) and not a vaccine adjuvant\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not the prolyl oligopeptidase ( POP ) inhibitor z-prolyl prolinal abolished the circulating levels of the peptide ( 27 )\\r\\n'\n",
      ">> b'In ribosome profiling , often referred to as RiboSeq , cells are lysed under conditions optimised to minimise further ribosome movement ( addition of translation inhibitors , rapid free\\r\\n'\n",
      ">> b'not changed by quercitrin , isoquercitrin and gallic acid ( Fig\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b\"without tears ('' '' arrived when niclosamide was introduced in the 1960 , followed by praziquantel a decade later\\r\\n\"\n",
      ">> b'not received antibiotics in the previous 4 to 6 weeks ) include the following choices : amoxicillin/clavulanate ( 1.75 to 4 g/250 mg per day ) , amoxicillin ( 1.5 to 4 g/day ) , cefpodoxime proxetil , cefuroxime axetil , or cefdinir\\r\\n'\n",
      ">> b'not received antibiotics in the previous 4 to 6 weeks include the following : high-dose amoxicillin/clavulanate ( 90 mg/6 .4 mg per kg per day ) , amoxicillin ( 90 mg/kg per day ) , cefpodoxime proxetil , cefuroxime axetil , or cefdinir\\r\\n'\n",
      ">> b'not received antibiotics in the previous 4 to 6 weeks include the following choices : amoxicillin / clavulanate ( 1.75 to 4 g/250 mg per day ) , amoxicillin ( 1.5 to 4 g/day ) , cefpodoxime proxetil , cefuroxime axetil , or cefdinir\\r\\n'\n",
      ">> b'not received antibiotics in the previous 4 to 6 weeks include the following choices : amoxicillin / clavulanate ( 1.75 to 4 g/250 mg per day ) , amoxicillin ( 1.5 to 4 g/day ) , cefpodoxime proxetil , cefuroxime axetil , or cefdinir\\r\\n'\n",
      ">> b'no-terminal amino acids of the protease are derived from the gag gene ; the fifth residue , glutamine , is derived through suppression of the in-frame amber termination codon located at the gag-pol junction ( 67 )\\r\\n'\n",
      ">> b'no FDA-approved vaccines for arenaviruses , and treatments have been limited to supportive therapy and use of non-specific nucleoside analogs , such as Ribavirin\\r\\n'\n",
      ">> b'without adverse consequences by adding rifampin to standard antistaphylococcal antimicrobial therapy\\r\\n'\n",
      ">> b'with no clear effect\\r\\n'\n",
      "--- remove CP\n",
      ">> b'not only inhibits HCV growth\n",
      ">> b'not approved in dogs and are not recommended to treat dogs with BPH because of potential side effects ( bone marrow suppression , prostatic metaplasia )\\r\\n'\n",
      ">> b'ruled out , and anestrus should be proven based on vaginal smears and progesterone plasma concentrations ( \\xcf\\xbd 2.0 ng/mL )\\r\\n'\n",
      ">> b'without harm to the fetuses\\r\\n'\n",
      ">> b'Only benzyl alcohol-free\\r\\n'\n",
      ">> b'without epinephrine is the most common local anesthetic administered\\r\\n'\n",
      ">> b'without epinephrine is the most common local anesthetic administered\\r\\n'\n",
      ">> b'no history of TB infection or treatment , and non-diabetic ) ( n = (NP-TMP 32,938 )\\r\\n'\n",
      ">> b'no history of TB infection or treatment , and non-diabetic ) ( n = (NP-TMP 32,938 )\\r\\n'\n",
      ">> b'no clonal antibodies ( eg , anti-interleukin 1\\xce\\xb2 , gevokizumab , anti-TNF\\xce\\xb1 , and adalimumab ) during the course of antibiotic treatment to clear the infection\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'absence of this neuropeptide in the medium when the culture was not treated with pepsin\\r\\n'\n",
      ">> b'not ( NT ) with 2 mg/ml doxorubicin or 1 nM camptothecin ( C and D )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not treated with the enzyme was due perhaps to reductions of the retinyl-lysine Schiff s base linkage\\r\\n'\n",
      ">> b'Participants were not excluded\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not Fenbendazole produces these effects at a mean inhibitory concentration ( IC 50 ) of 150 ng/ml , which might be an initial target for therapeutic CSF concentrations\\r\\n'\n",
      ">> b'Cases were excluded\\r\\n'\n",
      ">> b'Cases were excluded\\r\\n'\n",
      ">> b'no ) , specific type of side effect ( vomiting , diarrhea , decreased appetite , none ) and whether treatment was altered as a result\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'without hepatobiliary (NP-TMP disease , and normal cats repre - Sixty-nine studies , including seven conference abstracts , reporting perioperative and/or clinical and/or surgical/interventional outcomes of dogs managed with one surgical/interventional technique and/or medical management for cEHPSS were identified\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'no evidence that this is beneficial to the patient .\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'no evidence that this is beneficial to the patient .\\r\\n'\n",
      ">> b'not be a promising therapeutic agent for cardiopulmonary remodeling and PAH\\r\\n'\n",
      ">> b'not be a promising therapeutic agent for cardiopulmonary remodeling and PAH\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not have therapeutic plasma atenolol concentrations 2 hours after administration , and none had therapeutic plasma atenolol concentrations (NP-TMP 12 hours after administration\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not have therapeutic plasma atenolol concentrations 2 hours after administration , and none had therapeutic plasma atenolol concentrations (NP-TMP 12 hours after administration\\r\\n'\n",
      ">> b'not established abnormalities , even in children with abstinence syndrome on substitution therapy\\r\\n'\n",
      ">> b'no clinical improvement .\\r\\n'\n",
      ">> b'no clinical improvement .\\r\\n'\n",
      ">> b'no clinical improvement .\\r\\n'\n",
      ">> b'no effective therapeutic agent against CVB3 , and only ribavirin is available for CVB3 infection despite its weak antiviral activity -LSB- 93 -RSB-\\r\\n'\n",
      ">> b'no effective therapeutic agent against CVB3 , and only ribavirin is available for CVB3 infection despite its weak antiviral activity -LSB- 93 -RSB-\\r\\n'\n",
      ">> b'no liver failure occurred in members of this cohort\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'rather than suppressing the infection , are currently lacking\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not been highly successful ,\n",
      ">> b'not exhibit any therapeutic activity in CIA ( Figs\\r\\n'\n",
      ">> b'not exhibit any therapeutic activity in CIA ( Figs\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not recommended for subcutaneous administration because of extensive tissue damage ; the addition of dextrose to the administered calcium is also not recommended because it increases the tonicity of the solution and propensity for bacterial infection and development of abscesses\\r\\n'\n",
      ">> b'not be administered with tetracycline antibiotics because a yellow precipitate forms .\\r\\n'\n",
      ">> b'not required for a beneficial response\\r\\n'\n",
      ">> b'without electrolytes ; administration of tromethamine without electrolytes leads to hyponatremia , and it would appear preferable to administer tromethamine in conjunction with electrolytes .\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'Five percent dextrose is 250 mOsm/L as administered ,\n",
      ">> b'Calcium lactate does not appear\\r\\n'\n",
      ">> b'Calcium lactate does not appear\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'Hyponatremia can become severe when sodium-free\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not significantly different between the groups ( 27.1 % with Decitabine vs\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'without activation by its ligand , which can eventually lead to uncontrolled cell proliferation and a resistance to apoptosis\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not currently used to treat influenza virus infections because drug-resistant viruses can emerge rapidly ( both the A/H1N1pdm and A/H3N2 seasonal epidemic strains have the amantadine-resistance S31N mutation ) and the central nervous system side effects are particularly common in patients treated with amantadine .\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not currently used to treat influenza virus infections because drug-resistant viruses can emerge rapidly ( both the A/H1N1pdm and A/H3N2 seasonal epidemic strains have the amantadine-resistance S31N mutation ) and the central nervous system side effects are particularly common in patients treated with amantadine .\\r\\n'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ">> b'without focal segmental/lobar infiltrates\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no trehalose was treated with 2,3,4,6-tetra-O-acetyl-a-D-mannopyranosyl isothiocyanate , octavalent thiourea-bridged mannose cluster 84 was obtained after deprotection ( Figure 38 )\\r\\n'\n",
      ">> b'without the indicated stimulants\\r\\n'\n",
      ">> b'Briefly , MDCK cell monolayer cultured in 96-well plate was treated with ten-fold serially diluted BAL fluid ( 100 \\xce\\xbcl ) diluted in serum free\\r\\n'\n",
      ">> b'Briefly , MDCK cell monolayer cultured in 96-well plate was treated with ten-fold serially diluted BAL fluid ( 100 \\xce\\xbcl ) diluted in serum free\\r\\n'\n",
      ">> b'not received antibiotics in the previous 4 to 6 weeks include the following choices ( Table 4 ) : amoxicillin/clavulanate , amoxicillin ( 1.5 to 3.5 g/day ) , cefpo - doxime proxetil , or cefuroxime axetil\\r\\n'\n",
      ">> b'not received antibiotics in the previous 4 to 6 weeks include the following choices : amoxicillin/clavulanate , amoxicillin ( 3 to 3.5 g/day ) , cefpodoxime proxetil , or cefuroxime axetil\\r\\n'\n",
      ">> b'not received antibiotics in the previous 4 to 6 weeks include the following ( Table 5 ) : amoxicillin/clavulanate , amoxicillin ( 45 to 90 mg/kg per day ) , cefpodoxime proxetil , or cefuroxime axetil\\r\\n'\n",
      ">> b'not received antibiotics in the previous 4 to 6 weeks include the following ( Table 5 ) : amoxicillin/clavulanate , amoxicillin ( 45 to 90 mg/kg per day ) , cefpodoxime proxetil , or cefuroxime axetil\\r\\n'\n",
      ">> b'not received antibiotics in the previous 4 to 6 weeks include the following ( Table 5 ) : amoxicillin/clavulanate , amoxicillin ( 45 to 90 mg/kg per day ) , cefpodoxime proxetil , or cefuroxime axetil\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not improve , and subsequently is prescribed azithromycin when again there is still no improvement\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not improve , and subsequently is prescribed azithromycin when again there is still no improvement\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not improve , and subsequently is prescribed azithromycin when again there is still no improvement\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not improve , and subsequently is prescribed azithromycin when again there is still no improvement\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not improve , and subsequently is prescribed azithromycin when again there is still no improvement\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not improve , and subsequently is prescribed azithromycin when again there is still no improvement\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not improve , and subsequently is prescribed azithromycin when again there is still no improvement\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not improve , and subsequently is prescribed azithromycin when again there is still no improvement\\r\\n'\n",
      ">> b'not approved in the United States ) .\\r\\n'\n",
      ">> b'not approved in the United States ) .\\r\\n'\n",
      ">> b'not approved in the United States ) .\\r\\n'\n",
      ">> b'not approved in the United States ) .\\r\\n'\n",
      ">> b'not approved in the United States ) .\\r\\n'\n",
      ">> b'not approved in the United States ) .\\r\\n'\n",
      ">> b'not approved in the United States ) .\\r\\n'\n",
      ">> b'not approved in the United States ) .\\r\\n'\n",
      ">> b'absence of TMPRSS2 or treated with trypsin were pelleted by centrifugation at 1,200 rpm for 5 min\\r\\n'\n",
      ">> b'not be used thereafter\\r\\n'\n",
      ">> b'no differences in responses\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not treated with oseltamivir compared with 53 patients who received oseltamivir treatment , including 28 who were severely ill ( Supplementary Fig\\r\\n'\n",
      ">> b'without ribavirin ( RBV ) , a sustained viral response ( SVR ) was observed in 98 percent ( 42/43 ) of patients administered MK-5172 / MK-8742 alone and 94 percent ( 75/80 ) in those administered MK-5172 / MK-8742 plus RBV\\r\\n'\n",
      ">> b'without ribavirin ( RBV ) , a sustained viral response ( SVR ) was observed in 98 percent ( 42/43 ) of patients administered MK-5172 / MK-8742 alone and 94 percent ( 75/80 ) in those administered MK-5172 / MK-8742 plus RBV\\r\\n'\n",
      ">> b'without ribavirin ( RBV ) , a sustained viral response ( SVR ) was observed in 98 percent ( 42/43 ) of patients administered MK-5172 / MK-8742 alone and 94 percent ( 75/80 ) in those administered MK-5172 / MK-8742 plus RBV\\r\\n'\n",
      ">> b'not shown sufficient clinical activity to seek approval for the combination -LSB- 76 -RSB-\\r\\n'\n",
      ">> b'not shown sufficient clinical activity to seek approval for the combination -LSB- 76 -RSB-\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'without additional safety measures ( eg , pre-addition of hypochlorite ) , because any signifi cant concentrations of virus would be rapidly diluted within the hospital wastewater system and degraded by agents used for routine cleaning , and the theoretical risk to workers undertaking repairs could be managed by using properly trained , supervised , and equipped maintenance staff\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not induce uterine hypertrophy , and lower levels of biochemical markers of bone turnover ( e.g. , osteocalcin , alkaline phosphatase , C-terminal telopeptide fragment of type I collagen Cterminus ) were found in the group of rats treated with 309 than in ovariectomized rats , which suggests decreased bone turnover\\r\\n'\n",
      ">> b'not been replicated -LSB- 13 -RSB- .\\r\\n'\n",
      ">> b'nosis of hepatozoonosis was made , and unfortunately no ticks for species differentiation or further analyses were collected\\r\\n'\n",
      ">> b'without 1 % TX-100 at 4 \\xc2\\xb0C for 30 min were fractionated by discontinuous sucrose gradient centrifugation\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'absence of treatment ) , with a nonsignificant trend towards a beneficial effect on CD4 + counts in HIV-infected individuals ; 50 ( 2 ) a randomized , double-blind , placebo-controlled , cross-over trial of diethylcarbamazine for bancroftian filariasis , which reported a decrease in plasma HIV-1 RNA load ( and a nonsignificant trend towards a beneficial effect on CD4 + counts ) with treatment ; 51 and ( 3 ) a randomized , double-blind , placebocontrolled trial of albendazole for infection with diverse geohelminths ( including hookworms , Ascaris , and Trichuris ) , which found a nonsignificant trend towards a beneficial effect of treatment on plasma HIV-1 RNA load ,\n",
      ">> b'nom exerts antiosteoporotic effects on ovariectomized female albino rats treated with methylprednisolone\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no suckle reflex is present , the lamb should have 20 % dextrose administered into the intraperitoneal cavity\\r\\n'\n",
      ">> b'not against other hemorrhagic fever virus infections in humans (NP-TMP -LSB- 113 -RSB-\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not mainly attributable to autophagy\n",
      ">> b'with nonsaturating doses of inhibitors such as chloroquine , E-64d and bafilomycin A 1\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not desirable to treat cells with lysosomal inhibitors to determine rates of autophagic flux , a tandem mRFP/mCherry-EGFP-LC 3 ( or similar ) construct can also be used for autophagic flux measurements in flow cytometry experiments ( see Tandem mRFP/mCherry-GFP fluorescence microscopy )\\r\\n'\n",
      ">> b'Jet injectors are needle-free\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'nonimmuno suppressive analogs of cyclosporine A confirming that cyclophilins are valid biochemical targets for developing therapeutics for treating patients who are chronically infected with either HIV-1 or HCV\\r\\n'\n",
      "--- NP with that\n",
      "--- forced remove SBAR\n",
      ">> b'nonimmuno suppressive analogs of cyclosporine A confirming that cyclophilins are valid biochemical targets for developing therapeutics for treating patients who are chronically infected with either HIV-1 or HCV\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not a randomized control trial , this before and after study suggested an increase in more accurate oseltamivir prescribing for patients with influenza following the introduction of the POCT , which may be due to improved compliance with clinical guidelines ( NICE , 2009 )\\r\\n'\n",
      ">> b'not taxol 39\\r\\n'\n",
      ">> b'not be administered\\r\\n'\n",
      ">> b'without differences by gender in group 2\\r\\n'\n",
      ">> b'without differences by gender in group 2\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'declined to narrow therapy , because he lacked data showing that the organism was susceptible to an alternate agent , such as cefepime .\\r\\n'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ">> b'rather than cefuroxime 19 in patients at risk of DRSP\\r\\n'\n",
      ">> b'rather than cefuroxime 19 in patients at risk of DRSP\\r\\n'\n",
      ">> b'rather than cefuroxime 19 in patients at risk of DRSP\\r\\n'\n",
      ">> b'rather than cefuroxime 19 in patients at risk of DRSP\\r\\n'\n",
      ">> b'rather than cefuroxime 19 in patients at risk of DRSP\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'notherapy , and combination therapy should be with cefotaxime or ceftriaxone plus a macrolide ( azithromycin or erythromycin ) if pseudomonal risks are not present\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'notherapy , and combination therapy should be with cefotaxime or ceftriaxone plus a macrolide ( azithromycin or erythromycin ) if pseudomonal risks are not present\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'notherapy , and combination therapy should be with cefotaxime or ceftriaxone plus a macrolide ( azithromycin or erythromycin ) if pseudomonal risks are not present\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no risks of DRSP , therapy should be with an oral macrolide such as azithromycin , which is better tolerated than erythromycin\\r\\n'\n",
      ">> b'absence of large randomized , controlled studies .\\r\\n'\n",
      ">> b'not known\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'no et al. , 1997 As a previous trial with acyclovir showed no substantive clinical improvement in CFS pa-tients , poly ( I ) * poly ( ClzU ) ( Ampligen ) was evaluated as a potential therapeutic agent ( Suhadolnik et al. , 1994a ) .\\r\\n'\n",
      ">> b'without cisplatin ( 50 \\xce\\xbcM ) for 24 h according to the group assignment\\r\\n'\n",
      ">> b'not the CP ) and readthrough proteins ( indicated by the total size of the resulting protein ) are indicated\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not only suppresses T lymphocytes\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not only suppresses T lymphocytes\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not only suppresses T lymphocytes\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not only suppresses T lymphocytes\n",
      ">> b'not present ( Figure 4 )\\r\\n'\n",
      ">> b'not present ( Figure 4 )\\r\\n'\n",
      ">> b'neither the active antimicrobial agent ( CPC ) nor the barrier forming components ) administered intra-orally by spray (NP-TMP three times daily\\r\\n'\n",
      ">> b'neither the active antimicrobial agent ( CPC ) nor the barrier forming components ) administered intra-orally by spray (NP-TMP three times daily\\r\\n'\n",
      ">> b'not shown )\\r\\n'\n",
      ">> b'not treat this condition ( Aktas et al\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'absence of weight loss and changes in body temperature ) observed with free poly ( ICLC ) when administered i.v\\r\\n'\n",
      ">> b'nol ( 1c , 1e or 1a ) ( 20 mmol ) in dry acetonitrile ( 15 mL ) was treated with triethylamine ( 4.05 g , 40 mmol ) followed by the amino acid methyl ester isocyanate 3 ( 20 mmol )\\r\\n'\n",
      ">> b'no known specific anti-viral agent for the SARS-associated coronavirus , ribavirin has been widely used in treating adult cases in Hong Kong\\r\\n'\n",
      ">> b'not cholesterol , reversed this resistance\\r\\n'\n",
      ">> b'not cholesterol , reversed this resistance\\r\\n'\n",
      ">> b'without adverse side-effects .\\r\\n'\n",
      ">> b'without adverse side-effects .\\r\\n'\n",
      ">> b'Patients using metoclopramide , domperidone , cholestyramine or anticoagulation therapy were also excluded\\r\\n'\n",
      ">> b'Patients using metoclopramide , domperidone , cholestyramine or anticoagulation therapy were also excluded\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'\\xe2\\x80\\xa2 Aspirin and pseudoephedrine N = 236 \\xe2\\x80\\xa2 Aspirin N = 239 \\xe2\\x80\\xa2 Pseudoephedrine N = 237 \\xe2\\x80\\xa2 Placebo N = 121 Age : not stated Country : UK Inclusion criteria : nasal congestion and pain associated with upper respiratory tract infections for no more than 3 days Exclusion criteria : Allergic rhinitis , chronic respiratory disease , hyperthyroidism , cardiovascular disease , severe hypertension , peptic ulcer and hypersensitivity to acetylsalicylic acid , aspirin or pseudoephedrine Some medications were not allowed prior to the study entry : monoamine-oxidase inhibitors ( 30 days ) , antihistamines and antibiotics ( 7 days ) , analgesics and antipyretics ( 24 Eccles 2014 ( Continued ) hours ) , nasal decongestants ( 12 hours ) , lozenges and throat sprays ( 6 hours ) , menthol containing products ( 6 hours ) Patients under anti-coagulation therapy and pregnant or lactating females were also excluded\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'\\xe2\\x80\\xa2 Aspirin and pseudoephedrine N = 236 \\xe2\\x80\\xa2 Aspirin N = 239 \\xe2\\x80\\xa2 Pseudoephedrine N = 237 \\xe2\\x80\\xa2 Placebo N = 121 Age : not stated Country : UK Inclusion criteria : nasal congestion and pain associated with upper respiratory tract infections for no more than 3 days Exclusion criteria : Allergic rhinitis , chronic respiratory disease , hyperthyroidism , cardiovascular disease , severe hypertension , peptic ulcer and hypersensitivity to acetylsalicylic acid , aspirin or pseudoephedrine Some medications were not allowed prior to the study entry : monoamine-oxidase inhibitors ( 30 days ) , antihistamines and antibiotics ( 7 days ) , analgesics and antipyretics ( 24 Eccles 2014 ( Continued ) hours ) , nasal decongestants ( 12 hours ) , lozenges and throat sprays ( 6 hours ) , menthol containing products ( 6 hours ) Patients under anti-coagulation therapy and pregnant or lactating females were also excluded\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'\\xe2\\x80\\xa2 Aspirin and pseudoephedrine N = 236 \\xe2\\x80\\xa2 Aspirin N = 239 \\xe2\\x80\\xa2 Pseudoephedrine N = 237 \\xe2\\x80\\xa2 Placebo N = 121 Age : not stated Country : UK Inclusion criteria : nasal congestion and pain associated with upper respiratory tract infections for no more than 3 days Exclusion criteria : Allergic rhinitis , chronic respiratory disease , hyperthyroidism , cardiovascular disease , severe hypertension , peptic ulcer and hypersensitivity to acetylsalicylic acid , aspirin or pseudoephedrine Some medications were not allowed prior to the study entry : monoamine-oxidase inhibitors ( 30 days ) , antihistamines and antibiotics ( 7 days ) , analgesics and antipyretics ( 24 Eccles 2014 ( Continued ) hours ) , nasal decongestants ( 12 hours ) , lozenges and throat sprays ( 6 hours ) , menthol containing products ( 6 hours ) Patients under anti-coagulation therapy and pregnant or lactating females were also excluded\\r\\n'\n",
      ">> b'no approved therapeutics for any human CoV ( Chan et al. , 2013 ; de Wilde et al. , 2014 ; Shen et al. , 2016 )\\r\\n'\n",
      ">> b'no approved therapeutics for any human CoV ( Chan et al. , 2013 ; de Wilde et al. , 2014 ; Shen et al. , 2016 )\\r\\n'\n",
      ">> b'no approved therapeutics for any human CoV ( Chan et al. , 2013 ; de Wilde et al. , 2014 ; Shen et al. , 2016 )\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not rely on its proteolytic activity , as it is also the case for the RNA silencing suppression activity of the serine proteinase P1b of the ipomovirus CVYV ( Valli et al. , 2008 ) , illustrating how proteolysis-related and - unrelated roles can concur in a single viral protein\\r\\n'\n",
      "--- remove CP\n",
      ">> b'not common\n",
      "--- forced remove SBAR\n",
      ">> b'not be used to treat dogs with respiratory disease , even when CIV infection is present\\r\\n'\n",
      "--- forced remove SBAR\n",
      ">> b'not as effective as daily doses of 100 mg/kg of cidofovir that acts directly on vaccinia to inhibit replication\\r\\n'\n",
      ">> b'no change in the susceptibility pattern of strains isolated before and after therapy .\\r\\n'\n",
      ">> b'not IL-1b , TNF , or VCAM-1 ) in polyps from patients treated with intranasal fluticasone propionate\\r\\n'\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not generally very useful ,\n",
      "--- forced remove SBAR\n",
      "--- remove CP\n",
      ">> b'not generally very useful ,\n",
      ">> b'without proven efficacy\\r\\n'\n",
      ">> b'without proven efficacy\\r\\n'\n",
      ">> b'not available in North America , toltrazuril ( Baycox , Bayer Animal Health ) may be administered once at 30 mg/kg PO or 15 mg/kg PO once daily for 3 days\\r\\n'\n",
      ">> b'without a food or water bolus\\r\\n'\n",
      ">> b'without a food or water bolus\\r\\n'\n",
      ">> b'without a food or water bolus\\r\\n'\n",
      ">> b'ruled out and the practitioner is certain of the diagnosis of idiopathic disease , immune suppressive therapy can be increased by either increasing the dose of prednisolone or using other agents , such as chlorambucil , typically at 2 mg/cat , PO , (NP-TMP every second day\\r\\n'\n",
      ">> b'ruled out and the practitioner is certain of the diagnosis of idiopathic disease , immune suppressive therapy can be increased by either increasing the dose of prednisolone or using other agents , such as chlorambucil , typically at 2 mg/cat , PO , (NP-TMP every second day\\r\\n'\n"
     ]
    },
    {
     "ename": "ReadTimeout",
     "evalue": "HTTPConnectionPool(host='localhost', port=9001): Read timed out. (read timeout=60)",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mtimeout\u001b[0m                                   Traceback (most recent call last)",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\urllib3\\connectionpool.py\u001b[0m in \u001b[0;36m_make_request\u001b[1;34m(self, conn, method, url, timeout, chunked, **httplib_request_kw)\u001b[0m\n\u001b[0;32m    420\u001b[0m                     \u001b[1;31m# Otherwise it looks like a bug in the code.\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 421\u001b[1;33m                     \u001b[0msix\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mraise_from\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0me\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;32mNone\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    422\u001b[0m         \u001b[1;32mexcept\u001b[0m \u001b[1;33m(\u001b[0m\u001b[0mSocketTimeout\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mBaseSSLError\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mSocketError\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\urllib3\\packages\\six.py\u001b[0m in \u001b[0;36mraise_from\u001b[1;34m(value, from_value)\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\urllib3\\connectionpool.py\u001b[0m in \u001b[0;36m_make_request\u001b[1;34m(self, conn, method, url, timeout, chunked, **httplib_request_kw)\u001b[0m\n\u001b[0;32m    415\u001b[0m                 \u001b[1;32mtry\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 416\u001b[1;33m                     \u001b[0mhttplib_response\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mconn\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mgetresponse\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    417\u001b[0m                 \u001b[1;32mexcept\u001b[0m \u001b[0mBaseException\u001b[0m \u001b[1;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\http\\client.py\u001b[0m in \u001b[0;36mgetresponse\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m   1343\u001b[0m             \u001b[1;32mtry\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 1344\u001b[1;33m                 \u001b[0mresponse\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mbegin\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m   1345\u001b[0m             \u001b[1;32mexcept\u001b[0m \u001b[0mConnectionError\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\http\\client.py\u001b[0m in \u001b[0;36mbegin\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m    305\u001b[0m         \u001b[1;32mwhile\u001b[0m \u001b[1;32mTrue\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 306\u001b[1;33m             \u001b[0mversion\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mstatus\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mreason\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_read_status\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    307\u001b[0m             \u001b[1;32mif\u001b[0m \u001b[0mstatus\u001b[0m \u001b[1;33m!=\u001b[0m \u001b[0mCONTINUE\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\http\\client.py\u001b[0m in \u001b[0;36m_read_status\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m    266\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0m_read_status\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 267\u001b[1;33m         \u001b[0mline\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mstr\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mfp\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mreadline\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0m_MAXLINE\u001b[0m \u001b[1;33m+\u001b[0m \u001b[1;36m1\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;34m\"iso-8859-1\"\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    268\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0mlen\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mline\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;33m>\u001b[0m \u001b[0m_MAXLINE\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\socket.py\u001b[0m in \u001b[0;36mreadinto\u001b[1;34m(self, b)\u001b[0m\n\u001b[0;32m    588\u001b[0m             \u001b[1;32mtry\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 589\u001b[1;33m                 \u001b[1;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_sock\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mrecv_into\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mb\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    590\u001b[0m             \u001b[1;32mexcept\u001b[0m \u001b[0mtimeout\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mtimeout\u001b[0m: timed out",
      "\nDuring handling of the above exception, another exception occurred:\n",
      "\u001b[1;31mReadTimeoutError\u001b[0m                          Traceback (most recent call last)",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\requests\\adapters.py\u001b[0m in \u001b[0;36msend\u001b[1;34m(self, request, stream, timeout, verify, cert, proxies)\u001b[0m\n\u001b[0;32m    448\u001b[0m                     \u001b[0mretries\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mmax_retries\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 449\u001b[1;33m                     \u001b[0mtimeout\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mtimeout\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    450\u001b[0m                 )\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\urllib3\\connectionpool.py\u001b[0m in \u001b[0;36murlopen\u001b[1;34m(self, method, url, body, headers, retries, redirect, assert_same_host, timeout, pool_timeout, release_conn, chunked, body_pos, **response_kw)\u001b[0m\n\u001b[0;32m    719\u001b[0m             retries = retries.increment(\n\u001b[1;32m--> 720\u001b[1;33m                 \u001b[0mmethod\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0murl\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0merror\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0me\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0m_pool\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0m_stacktrace\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0msys\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mexc_info\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;36m2\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    721\u001b[0m             )\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\urllib3\\util\\retry.py\u001b[0m in \u001b[0;36mincrement\u001b[1;34m(self, method, url, response, error, _pool, _stacktrace)\u001b[0m\n\u001b[0;32m    399\u001b[0m             \u001b[1;32mif\u001b[0m \u001b[0mread\u001b[0m \u001b[1;32mis\u001b[0m \u001b[1;32mFalse\u001b[0m \u001b[1;32mor\u001b[0m \u001b[1;32mnot\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_is_method_retryable\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mmethod\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 400\u001b[1;33m                 \u001b[1;32mraise\u001b[0m \u001b[0msix\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mreraise\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtype\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0merror\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0merror\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0m_stacktrace\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    401\u001b[0m             \u001b[1;32melif\u001b[0m \u001b[0mread\u001b[0m \u001b[1;32mis\u001b[0m \u001b[1;32mnot\u001b[0m \u001b[1;32mNone\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\urllib3\\packages\\six.py\u001b[0m in \u001b[0;36mreraise\u001b[1;34m(tp, value, tb)\u001b[0m\n\u001b[0;32m    734\u001b[0m                 \u001b[1;32mraise\u001b[0m \u001b[0mvalue\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mwith_traceback\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtb\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 735\u001b[1;33m             \u001b[1;32mraise\u001b[0m \u001b[0mvalue\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    736\u001b[0m         \u001b[1;32mfinally\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\urllib3\\connectionpool.py\u001b[0m in \u001b[0;36murlopen\u001b[1;34m(self, method, url, body, headers, retries, redirect, assert_same_host, timeout, pool_timeout, release_conn, chunked, body_pos, **response_kw)\u001b[0m\n\u001b[0;32m    671\u001b[0m                 \u001b[0mheaders\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mheaders\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 672\u001b[1;33m                 \u001b[0mchunked\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mchunked\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    673\u001b[0m             )\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\urllib3\\connectionpool.py\u001b[0m in \u001b[0;36m_make_request\u001b[1;34m(self, conn, method, url, timeout, chunked, **httplib_request_kw)\u001b[0m\n\u001b[0;32m    422\u001b[0m         \u001b[1;32mexcept\u001b[0m \u001b[1;33m(\u001b[0m\u001b[0mSocketTimeout\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mBaseSSLError\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mSocketError\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 423\u001b[1;33m             \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_raise_timeout\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0merr\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0me\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0murl\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0murl\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mtimeout_value\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mread_timeout\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    424\u001b[0m             \u001b[1;32mraise\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\urllib3\\connectionpool.py\u001b[0m in \u001b[0;36m_raise_timeout\u001b[1;34m(self, err, url, timeout_value)\u001b[0m\n\u001b[0;32m    330\u001b[0m             raise ReadTimeoutError(\n\u001b[1;32m--> 331\u001b[1;33m                 \u001b[0mself\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0murl\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;34m\"Read timed out. (read timeout=%s)\"\u001b[0m \u001b[1;33m%\u001b[0m \u001b[0mtimeout_value\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    332\u001b[0m             )\n",
      "\u001b[1;31mReadTimeoutError\u001b[0m: HTTPConnectionPool(host='localhost', port=9001): Read timed out. (read timeout=60)",
      "\nDuring handling of the above exception, another exception occurred:\n",
      "\u001b[1;31mReadTimeout\u001b[0m                               Traceback (most recent call last)",
      "\u001b[1;32m<ipython-input-19-7bc6eff042b4>\u001b[0m in \u001b[0;36m<module>\u001b[1;34m\u001b[0m\n\u001b[0;32m     31\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     32\u001b[0m                         \u001b[1;31m# constituency tree parsing\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m---> 33\u001b[1;33m                         \u001b[0msl\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mtree_list\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mneg_part\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0msynparse\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mitem\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mdata_dir\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mneg_list\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mparser\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m     34\u001b[0m                         \u001b[0ms\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mre\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0msub\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m'\\([A-Z]*\\$? |\\(-[A-Z]+- |\\)|\\)|\\(, |\\(. '\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;34m''\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mstr\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mneg_part\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     35\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Documents\\GitHub\\task-vt\\negation_detection\\helper_functions.py\u001b[0m in \u001b[0;36msynparse\u001b[1;34m(item, data_dir, neg_list, parser)\u001b[0m\n\u001b[0;32m     44\u001b[0m             \u001b[1;32mfor\u001b[0m \u001b[0mi\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0ms\u001b[0m \u001b[1;32min\u001b[0m \u001b[0menumerate\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mll\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     45\u001b[0m                 \u001b[1;32mif\u001b[0m \u001b[0ms\u001b[0m \u001b[1;33m!=\u001b[0m \u001b[1;34m''\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m---> 46\u001b[1;33m                     \u001b[0mt\u001b[0m \u001b[1;33m=\u001b[0m \u001b[1;33m(\u001b[0m\u001b[0mnext\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mparser\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mraw_parse\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0ms\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m     47\u001b[0m                     \u001b[1;31m#fw.write(str(t))\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     48\u001b[0m                     \u001b[0mfw\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mwrite\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mstr\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mt\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mencode\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m'utf8'\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\nltk\\parse\\corenlp.py\u001b[0m in \u001b[0;36mraw_parse\u001b[1;34m(self, sentence, properties, *args, **kwargs)\u001b[0m\n\u001b[0;32m    229\u001b[0m         return next(\n\u001b[0;32m    230\u001b[0m             self.raw_parse_sents(\n\u001b[1;32m--> 231\u001b[1;33m                 \u001b[1;33m[\u001b[0m\u001b[0msentence\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mproperties\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mdefault_properties\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m*\u001b[0m\u001b[0margs\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    232\u001b[0m             )\n\u001b[0;32m    233\u001b[0m         )\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\nltk\\parse\\corenlp.py\u001b[0m in \u001b[0;36mraw_parse_sents\u001b[1;34m(self, sentences, verbose, properties, *args, **kwargs)\u001b[0m\n\u001b[0;32m    284\u001b[0m                 \u001b[1;32myield\u001b[0m \u001b[0miter\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m[\u001b[0m\u001b[0mtree\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    285\u001b[0m         \"\"\"\n\u001b[1;32m--> 286\u001b[1;33m         \u001b[0mparsed_data\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mapi_call\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m'\\n'\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mjoin\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0msentences\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mproperties\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mdefault_properties\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    287\u001b[0m         \u001b[1;32mfor\u001b[0m \u001b[0mparsed_sent\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mparsed_data\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;34m'sentences'\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    288\u001b[0m             \u001b[0mtree\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mmake_tree\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mparsed_sent\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\nltk\\parse\\corenlp.py\u001b[0m in \u001b[0;36mapi_call\u001b[1;34m(self, data, properties, timeout)\u001b[0m\n\u001b[0;32m    247\u001b[0m             \u001b[0mparams\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;33m{\u001b[0m\u001b[1;34m'properties'\u001b[0m\u001b[1;33m:\u001b[0m \u001b[0mjson\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mdumps\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mdefault_properties\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m}\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    248\u001b[0m             \u001b[0mdata\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mdata\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mencode\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mencoding\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 249\u001b[1;33m             \u001b[0mtimeout\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mtimeout\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    250\u001b[0m         )\n\u001b[0;32m    251\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\requests\\sessions.py\u001b[0m in \u001b[0;36mpost\u001b[1;34m(self, url, data, json, **kwargs)\u001b[0m\n\u001b[0;32m    579\u001b[0m         \"\"\"\n\u001b[0;32m    580\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 581\u001b[1;33m         \u001b[1;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mrequest\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m'POST'\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0murl\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mdata\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mdata\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mjson\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mjson\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    582\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    583\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0mput\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0murl\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mdata\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;32mNone\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\requests\\sessions.py\u001b[0m in \u001b[0;36mrequest\u001b[1;34m(self, method, url, params, data, headers, cookies, files, auth, timeout, allow_redirects, proxies, hooks, stream, verify, cert, json)\u001b[0m\n\u001b[0;32m    531\u001b[0m         }\n\u001b[0;32m    532\u001b[0m         \u001b[0msend_kwargs\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mupdate\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0msettings\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 533\u001b[1;33m         \u001b[0mresp\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0msend\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mprep\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0msend_kwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    534\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    535\u001b[0m         \u001b[1;32mreturn\u001b[0m \u001b[0mresp\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\requests\\sessions.py\u001b[0m in \u001b[0;36msend\u001b[1;34m(self, request, **kwargs)\u001b[0m\n\u001b[0;32m    644\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    645\u001b[0m         \u001b[1;31m# Send the request\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 646\u001b[1;33m         \u001b[0mr\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0madapter\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0msend\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mrequest\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    647\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    648\u001b[0m         \u001b[1;31m# Total elapsed time of the request (approximately)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\requests\\adapters.py\u001b[0m in \u001b[0;36msend\u001b[1;34m(self, request, stream, timeout, verify, cert, proxies)\u001b[0m\n\u001b[0;32m    527\u001b[0m                 \u001b[1;32mraise\u001b[0m \u001b[0mSSLError\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0me\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mrequest\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mrequest\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    528\u001b[0m             \u001b[1;32melif\u001b[0m \u001b[0misinstance\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0me\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mReadTimeoutError\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 529\u001b[1;33m                 \u001b[1;32mraise\u001b[0m \u001b[0mReadTimeout\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0me\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mrequest\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mrequest\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    530\u001b[0m             \u001b[1;32melse\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    531\u001b[0m                 \u001b[1;32mraise\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mReadTimeout\u001b[0m: HTTPConnectionPool(host='localhost', port=9001): Read timed out. (read timeout=60)"
     ]
    }
   ],
   "source": [
    "for filename in filenames:\n",
    "    data = pd.read_csv(data_dir+filename, index_col=False)\n",
    "\n",
    "    output_data = data\n",
    "\n",
    "    print(datetime.datetime.now())\n",
    "\n",
    "    for i in range(0,len(data)):\n",
    "        if pd.isnull(data.loc[i,'sentence']):\n",
    "            output_data.loc[i,'Is_Negated'] = 0\n",
    "        else:\n",
    "            output = nlp.annotate(data.loc[i,'sentence'], properties={\n",
    "                                                      'annotators': 'ssplit',\n",
    "                                                      'outputFormat': 'json',\n",
    "                                                      'threads': '4',\n",
    "                                                      'tokenize.options': 'normalizeParentheses=false, normalizeOtherBrackets=false'\n",
    "                                                      })\n",
    "            sents = [[str(token['word']) for token in sent['tokens']] for sent in output['sentences']]\n",
    "            sent_output = [' '.join(sent) for sent in sents if sent != ['.']]\n",
    "\n",
    "            for item in sent_output:\n",
    "                # tag negated or affirmed based on string matching --- negation term list\n",
    "                # add one space to prevent loss of 'no ', 'not ', ... etc.\n",
    "                for j, substring in enumerate(neg_term):\n",
    "                    if substring in ' ' + item:\n",
    "                        output_data.loc[i,'Is_Negated'] = 1\n",
    "                        output_data.loc[i, 'Negation_Term'] = substring\n",
    "\n",
    "                        neg_type = neg_list.loc[neg_list.ITEM == substring.strip(),'TYPE'].values[0]\n",
    "                        output_data.loc[i, 'Negated_Type'] = neg_type\n",
    "                        \n",
    "                        # constituency tree parsing\n",
    "                        sl, tree_list, neg_part = synparse(item, data_dir, neg_list, parser)\n",
    "                        s = re.sub('\\([A-Z]*\\$? |\\(-[A-Z]+- |\\)|\\)|\\(, |\\(. ', '', str(neg_part[0]))\n",
    "                        \n",
    "                        if pd.isnull(neg_type)==False:\n",
    "                            # run tregex/tsurgeon based on the selected neg type\n",
    "                            ts_out, tree = tregex_tsurgeon(data_dir + 'tmp_neg_tree', neg_type, trts)\n",
    "\n",
    "                            # deal with corner cases\n",
    "                            if neg_type == 'NP' and ('that' in ts_out):\n",
    "                                print('--- NP with that')\n",
    "                                ts_out, tree = tregex_tsurgeon(data_dir + 'tmp_neg_tree', 'NP-denies', trts)\n",
    "                            if neg_type == 'NP' and s == ts_out:\n",
    "                                print('--- NP without S node')\n",
    "                                ts_out, tree = tregex_tsurgeon(data_dir + 'tmp_neg_tree', 'NP-nS', trts)\n",
    "\n",
    "                            if neg_type == 'PP' and sum([item in neg_list['ITEM'].tolist() for item in ts_out.split()]) > 0:\n",
    "                                print('--- NP without S node')\n",
    "                                ts_out, tree = tregex_tsurgeon(data_dir + 'tmp_neg_tree', 'NP-nS', trts)\n",
    "\n",
    "                            if neg_type == 'VP-A' and s == ts_out:\n",
    "                                print('--- VP-A remove denies')\n",
    "                                ts_out, tree = tregex_tsurgeon(data_dir + 'tmp_neg_tree', 'NP-denies', trts)\n",
    "\n",
    "                            if neg_type == 'ADVP-A' and s == ts_out:\n",
    "                                print('--- ADVP-A type 2')\n",
    "                                ts_out, tree = tregex_tsurgeon(data_dir + 'tmp_neg_tree', 'ADVP-A2', trts)\n",
    "                            if neg_type == 'ADVP-A' and s == ts_out:\n",
    "                                print('--- ADVP-A remove SBAR')\n",
    "                                ts_out, tree = tregex_tsurgeon(data_dir + 'tmp_neg_tree', 'ADVP-sbar', trts)\n",
    "                            if neg_type == 'ADVP-A' and s == ts_out: # no longer\n",
    "                                print('--- ADVP-A remove ADVP')\n",
    "                                ts_out, tree = tregex_tsurgeon(data_dir + 'tmp_neg_tree', 'ADVP-advp', trts)\n",
    "                            if neg_type == 'ADVP-A' and s == ts_out:\n",
    "                                print('--- ADVP-A remove RB')\n",
    "                                ts_out, tree = tregex_tsurgeon(data_dir + 'tmp_neg_tree', 'ADVP-RB', trts)\n",
    "\n",
    "                            if 'SBAR' in tree:\n",
    "                                print('--- forced remove SBAR')\n",
    "                                ts_out, tree = tregex_tsurgeon(data_dir + 'tmp_neg_tree', 'forced-sbar', trts)\n",
    "\n",
    "                            if sum([item in RM_POS for item in ts_out.split()]) > 0:\n",
    "                                print('--- remove POS')\n",
    "                                ts_out = ' '.join(ts_out.split()[1:])\n",
    "\n",
    "                            if sum([item in RM_CP for item in ts_out.split()]) > 0:\n",
    "                                print('--- remove CP')\n",
    "                                for cp in RM_CP:\n",
    "                                    try:\n",
    "                                        cp_loc = ts_out.split().index(cp)\n",
    "                                    except:\n",
    "                                        continue\n",
    "                                ts_out = ' '.join(ts_out.split()[:cp_loc])\n",
    "\n",
    "                            if ts_out.split()[0] in neg_list['ITEM'].tolist() + stopwords:\n",
    "                                print('--- remove first token f if f in negated list or stopword list')\n",
    "                                ts_out = ' '.join(ts_out.split()[1:])\n",
    "                            if neg_type == 'VP-A' and len(ts_out) < 2:\n",
    "                                print('--- VP-A CC')\n",
    "                                ts_out, tree = tregex_tsurgeon(data_dir + 'ntree_tmp', 'VP-CC', trts)\n",
    "\n",
    "                            output_data.loc[i, 'Negated_Part'] = str(ts_out)\n",
    "\n",
    "                            print('>> ' + ts_out)\n",
    "                            \n",
    "                        else:\n",
    "                            output_data.loc[i, 'Negated_Part'] = ''\n",
    "                        \n",
    "                        break\n",
    "                        \n",
    "                    else:\n",
    "                        output_data.loc[i,'Is_Negated'] = 0\n",
    "                        output_data.loc[i, 'Negation_Term'] = ''\n",
    "                        output_data.loc[i, 'Negated_Type'] = ''\n",
    "                        output_data.loc[i, 'Negated_Part'] = ''\n",
    "\n",
    "    print(datetime.datetime.now())\n",
    "\n",
    "    # remove file extension from file name and save results in an output file\n",
    "    output_data.to_csv(out_dir + filename[:-4] + '_Negated_Output_Parsed.csv',index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "output_data.to_csv(out_dir + filename[:-4] + '_Negated_Output_Parsed.csv',index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "negated_drug_mentions = output_data.loc[output_data.Is_Negated==1,'drug']\\\n",
    "                                    .groupby(output_data['drug'])\\\n",
    "                                    .value_counts()\\\n",
    "                                    .droplevel(level=0)\n",
    "print('Top 20 most negated drugs:\\n')\n",
    "print(negated_drug_mentions.nlargest(20))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "asserted_drug_mentions = output_data.loc[output_data.Is_Negated==0,'drug']\\\n",
    "                                    .groupby(output_data['drug'])\\\n",
    "                                    .value_counts()\\\n",
    "                                    .droplevel(level=0)\n",
    "print('Top 20 most asserted drugs:\\n')\n",
    "print(asserted_drug_mentions.nlargest(20))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Pros:\n",
    "- quick and easy\n",
    "- curated list of trigger terms for the medical context which includes words like \"ineffective\", that are not recognized \n",
    "  as negation by standard dependancy parsing libraries such as scispacy\n",
    "- could potentially capture cases such as\n",
    "    (a) sentences with buts\n",
    "    (b) comparison of drugs\n",
    "    (c) when there is a negation word which is unrelated to the drug Eg. \"The drug is recommended in cases where the patient is not suffering from a prior chronical disease\"\n",
    "\n",
    "#### Cons:\n",
    "- does not capture cases such as \n",
    "    (d) when negation is understood only with prior medical knowledge\n",
    "    (e) double negation Eg. \"not ineffective\" or \"not useless\"\n",
    "- false negatives when the negated part extracted does not contain the drug name"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
